Neu auf wallstreet:online? Jetzt kostenlos registrieren!
Registrieren | Login
x
Benutzername:

Passwort:

Angemeldet bleiben
Passwort vergessen?

    CELL GENESYS -GVAX - 500 Beiträge pro Seite

    eröffnet am 30.03.07 16:17:05 von
    asics01

    neuester Beitrag 02.10.09 11:08:24 von
    Larry_1
    Beiträge: 231
    ID: 1.122.092
    Aufrufe heute: 0
    Gesamt: 26.674

    Neuigkeiten zu


    Beitrag schreiben Ansicht: 500 Beiträge pro Seite
    Avatar
    asics01
    schrieb am 30.03.07 16:17:05
    Beitrag Nr. 1 (28.586.590)
    CELL GENESYS dürfte nun nach dem erfolg von PROVENGE mit ihrem Vaccin-GVAX nun auch in das Rampenlicht rücken.Phase3 gegen Prostatakrebs
    und der Rest der Pipline ist auch nicht ohne.
    asics
    Avatar
    asics01
    schrieb am 30.03.07 19:04:46
    Beitrag Nr. 2 (28.590.741)
    man vermutet dass gvax bereits 2008 auf den markt kommen könnte
    Avatar
    asics01
    schrieb am 31.03.07 18:18:38
    Beitrag Nr. 3 (28.602.398)
    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapy for pancreatic cancer and leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.
    Avatar
    bucketshop
    schrieb am 02.04.07 22:15:49
    Beitrag Nr. 4 (28.630.916)
    Antwort auf Beitrag Nr.: 28.602.398 von asics01 am 31.03.07 18:18:38Na wenn da nicht mal was im Buscht ist. Heute war die web cast Konferenz (Lehman Brothers) um 2.30 . Seit dem ist der Kurs in den USA bei recht gutem Volumen nach oben gegangen und hat fast im Tageshoch geschlossen, das lässt Gutes hoffen für morgen. Wenn am Donnerstag das Aproval von der FDA kommt, knallen die Korken. CEGE dürfte dann eine vergleichbare Tagesperformance hinlegen wie Dendreon Corp. (DNDN) die am Freitag von 5 auf 19 USD gestiegen ist. In CEGE besteht derzeit eine short position von über 7 Mio aktien. Die Hedge Fonds werden bei positiven Ausgang am Donnerstag für ein Blutbad sorgen.

    Viel Glück
    Avatar
    cyberhai
    schrieb am 03.04.07 08:54:58
    Beitrag Nr. 5 (28.632.998)
    Antwort auf Beitrag Nr.: 28.630.916 von bucketshop am 02.04.07 22:15:49Ich habe nichts von dem Termin am Donnerstag gefunden, hast Du eine Quelle?
    Avatar
    Cyberhexe
    schrieb am 03.04.07 13:46:23
    Beitrag Nr. 6 (28.638.468)
    ...hab mir auch einmal eine kleine Position aufgebaut!
    Avatar
    asics01
    schrieb am 03.04.07 16:13:37
    Beitrag Nr. 7 (28.641.909)
    ich finde auch nichts,aber etwas ist im busch ohne grund ziehen die CEGE nicht so hoch.
    Avatar
    rafelguraf
    schrieb am 03.04.07 16:39:02
    Beitrag Nr. 8 (28.642.674)
    ... die Testergebnisse von GVAX sind ganz gut, Lebenserwartung von Patienten konnte gesteigert werden

    http://biz.yahoo.com/ap/070403/cell_genesys_gvax.html
    Avatar
    Cyberhexe
    schrieb am 03.04.07 17:54:30
    Beitrag Nr. 9 (28.644.607)
    Additional follow-up of the 22 patients who received the dose that is comparable to that being employed in the company's ongoing Phase 3 program indicates that the median survival is 35.0 months.


    http://phx.corporate-ir.net/phoenix.zhtml?c=98399&p=irol-new…

    ...diese Ergebnisse sind sehr viel versprechend. Da darf man auf die ersten Daten der Phase-III-Studien gespannt sein!
    Avatar
    asics01
    schrieb am 03.04.07 19:45:38
    Beitrag Nr. 10 (28.646.922)
    CEGE hebt ab:):)
    Avatar
    asics01
    schrieb am 03.04.07 20:30:29
    Beitrag Nr. 11 (28.647.875)
    nach dem coup von dndn rückt jetzt natürlich auch dank den super news CEGE mit ins rampenlicht,CEGE ist doch jetzt bestimmt interessant für big pharma???
    Avatar
    asics01
    schrieb am 03.04.07 20:39:50
    Beitrag Nr. 12 (28.648.023)
    aber was auch schön ist, dass heute wieder ein paar shorties auf dem falschen fuss erwischt wurden:laugh::kiss::D
    Avatar
    Crazy777
    schrieb am 03.04.07 22:48:36
    Beitrag Nr. 13 (28.650.047)
    Cell Genesys hat immer noch Potenzial bis 10 USD.
    Wenn GVAX zugelassen wird ist noch Luft bis 25-30 USD.
    Also ist noch einiges drinnen.

    Aber schaut euch mal Favrille (FVRL) an:
    - Mcap. bei rund 100 Mio. USD
    - Buchwert bei ca. 60 USD
    - Und v.a. ein Medikament in der Pipeline in Phase 3 dass ähnlich wie GVAX wirkt und auch gute Ergebnisse geliefert hat.
    Ganz wichtig ist hier noch zu sagen, dass dieses Medikament gegen Lymphdrüsenkrebs wirkt, also keine Konkurrenz zu Provence oder GVAX darstellt.
    Deswegen schätze ich hier das Potenziel noch höher ein.
    Mein Kursziel sind hier kurzfristig die 10 und langfristig die 50 USD.

    Bin schon in beiden Werten drin.
    Avatar
    asics01
    schrieb am 09.04.07 18:10:09
    Beitrag Nr. 14 (28.729.403)
    CEGE hebt ab :kiss::lick:
    Avatar
    asics01
    schrieb am 09.04.07 18:54:58
    Beitrag Nr. 15 (28.729.889)
    mich freut der kurssprung natürlich sehr,aber man kanns auch übertreiben oder???
    Avatar
    whyso
    schrieb am 10.04.07 12:45:01
    Beitrag Nr. 16 (28.737.993)
    Antwort auf Beitrag Nr.: 28.729.889 von asics01 am 09.04.07 18:54:58Wieso Übertrieben?

    CEGE:


    DNDN:


    NUVO


    SIGA:


    Achte auf SIGA auch....;)-hier sind wir in die Entstehungsphase (Ausbruchsphase befindlich)- meiner bescheidener Meinung nach, alle vier Werte sind hot z.Zt

    Steigende Grüße,
    Whyso:cool:
    Avatar
    asics01
    schrieb am 12.04.07 18:44:49
    Beitrag Nr. 17 (28.781.365)
    CEGE im gleichschritt mit DNDN,was passiert mit CEGE im Falle einer Zulassung von Provenge???Ist GVAX besser wie Provenge???
    Avatar
    asics01
    schrieb am 12.04.07 18:47:49
    Beitrag Nr. 18 (28.781.404)
    Antwort auf Beitrag Nr.: 28.781.365 von asics01 am 12.04.07 18:44:49oder was passiert bei einer nichtzulassung von Provenge mit CEGE???
    Avatar
    asics01
    schrieb am 04.05.07 19:25:45
    Beitrag Nr. 19 (29.139.334)
    ziemlich ruhig hier


    Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
    SOUTH SAN FRANCISCO, Calif., April 17 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer. In addition, the antibody responses to this non patient- specific product were predominantly patient-specific and unique from patient to patient, indicating the potential advantage of a cell-based multi-antigen product such as GVAX to generate the broadest and most relevant immune response. Serological analysis of gene expression (SEREX) technology was also used to identify target antigens involved in response to the immunotherapy. More than 148 proteins to which antibody responses were induced were identified and many of these proteins had not been identified previously as prostate cancer-associated antigens. These findings were presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the annual meeting of the American Association for Clinical Research being held in Los Angeles, CA.

    GVAX immunotherapy for prostate cancer is currently being studied both as a single agent and in combination with docetaxel chemotherapy in two Phase 3 clinical trials targeted to enroll approximately 1200 patients with metastatic hormone-refractory prostate cancer (HRPC). This ongoing Phase 3 program is supported by the median survival results from two, independent, multi-center Phase 2 clinical trials. Cell Genesys recently reported final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer, which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC). Additional follow-up of the 22 patients who received the dose that is comparable to that being employed in the company's ongoing Phase 3 program revealed that their median survival is 35.0 months. Four patients have withdrawn consent to further follow-up and thus were censored in the analysis. The company also has previously reported final median survival results from its first multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer in 34 patients with metastatic HRPC that showed an overall median survival of 26.2 months. The survival results from the two, independent multi-center Phase 2 clinical trials compare favorably to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus prednisone, the current standard of care for these patients. The company's ongoing Phase 3 program is designed to confirm this potential survival benefit of GVAX immunotherapy for prostate cancer.

    "The immune response data reported today provide added support for the concept that a whole-cell immunotherapy, such as GVAX immunotherapy for prostate cancer, is an ideal multi-antigen source that is capable of eliciting an immune response to a broad array of tumor-associated antigens," stated Peter K. Working, Ph.D., senior vice president of Research and Development at Cell Genesys. "That the majority of antibody responses are unique to individual patients is further evidence that the non patient-specific format of GVAX immunotherapies is capable of inducing unique, patient-specific immune responses. Moreover, the fact that many of these antigens have not before been associated with prostate cancer, further suggests that a multivalent antigen immunotherapy like GVAX immunotherapy may provide the best potential for inducing an effective anti-tumor immune response, especially for heterogeneous cancers such as prostate cancer."

    Evidence of patient-specific immune responses associated with non patient- specific GVAX immunotherapy products has also been reported in other cancers. In August 2004, the company reported on data published in the Journal of Experimental Medicine from a Phase 1 clinical trial of GVAX immunotherapy for pancreatic cancer that provided evidence that patient-specific immune responses can be generated following treatment with this non patient-specific product. The article described detailed analyses of the immune response to the immunotherapy in three out of 14 patients who were long-term survivors and who also demonstrated strong T cell responses to mesothelin, a tumor- associated protein found in the majority of pancreatic cancers and in the GVAX immunotherapy for pancreatic cancer cells. The specificity of the T cell response to mesothelin was shown to be unique to each responding patient providing further scientific proof-of-concept for the company's GVAX immunotherapy strategy.

    GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

    Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

    Contact: Ina Cu
    Investor Relations
    650-266-3200

    SOURCE Cell Genesys, Inc.
    04/17/2007
    /CONTACT: Ina Cu, Investor Relations of Cell Genesys, Inc.,
    +1-650-266-3200
    /Web site: http://www.cellgenesys.com
    (CEGE)

    CO: Cell Genesys, Inc.
    ST: California
    IN: HEA BIO
    SU: TRI TDS

    HD
    -- SFTU061 --
    7462 04/17/2007 07:00 EDT http://www.prnewswire.com




    About Us | Product Progress | Patient Information | Investor's Corner | Career Opportunities
    ©2006 Cell Genesys, Inc. | Site Design: Heiney & Craig, Inc. | Home | Search | Contact Us
    Avatar
    asics01
    schrieb am 09.05.07 16:54:13
    Beitrag Nr. 20 (29.234.895)
    DENDREON lässt grüssen:cry::cry:
    Avatar
    asics01
    schrieb am 09.05.07 17:06:23
    Beitrag Nr. 21 (29.235.214)
    hoffentlich machen die es besser, und ist GVAX besser:cool::cool:
    Avatar
    asics01
    schrieb am 20.08.07 18:34:09
    Beitrag Nr. 22 (31.231.135)
    Cell Genesys Completes Patient Recruitment for First Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
    SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that it has completed recruitment of over 600 patients into VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer.

    The multi-center, randomized, controlled Phase 3 study in advanced prostate cancer will compare GVAX cancer immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus prednisone in hormone refractory prostate cancer (HRPC) patients with metastatic disease. The primary endpoint of the trial is an improvement in survival.

    "Entering this final stage of patient recruitment for the first of our two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer is an important milestone for the program, and we are very grateful to the men with prostate cancer and their physicians involved in this trial as well as the Cell Genesys employees who have made this possible," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "With the completion of patient recruitment behind us, we can now estimate the timing of the pre-planned interim analysis for the VITAL-1 trial to be in 2008, probably during the first half of the year, and that we will have a sufficient number of events required for the final analysis to follow sometime later in 2009."

    Cell Genesys received Fast Track designation from the U.S. Food and Drug Administration for GVAX immunotherapy for prostate cancer and Special Protocol Assessments for VITAL-1 and VITAL-2, the second ongoing Phase 3 study currently under way at approximately 90 sites in the United States, Canada and Europe. VITAL-2 is enrolling metastatic HRPC patients who are symptomatic with cancer-related pain. The study will compare GVAX cancer immunotherapy plus Taxotere chemotherapy to Taxotere plus prednisone. The primary endpoint of the study is an improvement in survival. The company expects to recruit approximately 600 patients into VITAL-2 and plans to update the timeline for the completion of recruitment by the end of 2007.

    Cell Genesys' ongoing Phase 3 GVAX immunotherapy for prostate cancer program is supported by the median survival results from two, independent, multi-center Phase 2 clinical trials in approximately 115 patients. The subset of patients in these two trials who received the doses comparable to the Phase 3 dose showed median survival of 34.9 months and 35.0 months, respectively. These results also exceeded the predicted survival of 22.5 months and 22.0 months, respectively, as determined by a seven point patient disease characteristic nomogram. The results of the first trial were published in the July 1 issue of Clinical Cancer Research. Results from both studies compare favorably to the previously published median survival of 18.9 months for metastatic HRPC patients treated with Taxotere chemotherapy plus prednisone, the current standard of care. Moreover, as previously reported, the safety profile observed in Phase 2 trials of GVAX immunotherapy for prostate cancer compares favorably with that reported for chemotherapy. The Phase 3 program is designed to confirm a potential survival benefit and safety profile for GVAX immunotherapy for prostate cancer.

    About GVAX Immunotherapy for Prostate Cancer

    Cell Genesys' GVAX cancer immunotherapies are whole-cell products that are designed to present the immune system with a broad spectrum of tumor antigens and stimulate an immune response against the patient's tumor. GVAX immunotherapy for prostate cancer is comprised of two prostate tumor cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone which plays a key role in stimulating the body's immune response, and then are irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product. The company is currently manufacturing GVAX immunotherapy for prostate cancer in its bioreactor manufacturing facility in Hayward, California, a facility that is also capable of producing the product during its initial commercialization.

    About Cell Genesys

    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms - GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

    Statements in this press release which are not strictly historical are forward-looking statements, including statements about the company's progress, timing and results of clinical trials (such as the analysis for the VITAL-1 trial) and pre-clinical programs, and the nature and prospects of product pipelines. As such, they are subject to significant risks and uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional funding. For information about these and other risks which may affect Cell Genesys, please see the company's Securities and Exchange Commission filings, including Forms 10-K, 10-Q, 8-K, and other SEC filings. Cell Genesys assumes no obligation to update the forward-looking statements in this press release.

    Contact:

    Susan Ferris
    Investor Relations
    650-266-3200

    SOURCE Cell Genesys, Inc.
    07/10/2007
    CONTACT: Susan Ferris, Investor Relations of Cell Genesys,
    +1-650-266-3200/
    Web site: http://www.cellgenesys.com
    (CEGE)





    About Us | Product Progress | Patient Information | Investor's Corner | Career
    Avatar
    asics01
    schrieb am 20.08.07 18:52:25
    Beitrag Nr. 23 (31.231.298)
    Cell Genesys Reports Second Quarter 2007 Results
    SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today reported financial results for the second quarter ended June 30, 2007. The company reported a net loss of $1.9 million, or $0.03 per fully diluted share, for the second quarter of 2007, compared with a net loss of $27.9 million, or $0.60 per fully diluted share, in the corresponding period of 2006.

    The decrease in net loss reported in the second quarter of 2007 compared with the net loss for the corresponding period in the previous year is due to a favorable settlement with the Internal Revenue Service (IRS) in the second quarter of 2007 relating to the company's 2000 tax return. The settlement resulted in a decrease of approximately $26.8 million in accrued income tax liabilities following a payment to the IRS of $3.3 million in federal tax and interest.

    "We are very pleased with our recent business progress, most notably the completion of patient recruitment in the first of two ongoing Phase 3 trials of our lead product, GVAX immunotherapy for prostate cancer. This is a major milestone for this program and our business in general," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "We are equally pleased that we have been able to maintain our financial strength as we advance this key development program with a successful equity financing during the quarter."

    Revenues for the second quarter ended June 30, 2007, were less than $0.1 million compared with revenues of $1.0 million for the corresponding period in 2006. The difference is due to the timing of revenue from existing licensing arrangements which varies from quarter to quarter.

    The company's research and development costs were $25.0 million for the second quarter of 2007 compared with $23.2 million for the corresponding period in 2006. The increase is primarily due to expenses related to the ongoing Phase 3 clinical trials of the company's lead product development program, GVAX immunotherapy for prostate cancer. General and administrative expenses were $4.8 million for the second quarter of 2007 compared to $4.3 million for the corresponding period in 2006. This increase is primarily attributed to an increase in administrative expenses.

    As of June 30, 2007, Cell Genesys had approximately $171.1 million in cash, cash equivalents and short-term investments compared to $154.1 million at December 31, 2006. The ending second quarter balance reflects gross proceeds raised since the beginning of 2007, including $12.5 million raised in the first quarter from the company's Committed Equity Financing Facilities with Kingsbridge Capital Limited, and $60.0 million raised from a registered direct offering in the second quarter.

    Second Quarter and Other Recent Highlights

    -- Announced the completion of recruitment of over 600 patients into
    VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX
    immunotherapy for prostate cancer. The multi-center, randomized,
    controlled Phase 3 study in advanced prostate cancer will compare GVAX
    cancer immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus
    prednisone in hormone refractory prostate cancer (HRPC) patients with
    metastatic disease. The primary endpoint of the trial is an improvement
    in survival. The company estimates the timing of the pre-planned
    interim analysis from the VITAL-1 trial to be in 2008, probably in the
    first half of the year, and that there will be a sufficient number of
    events required for the final analysis to follow sometime later in
    2009.

    -- Reported updated clinical data for GVAX immunotherapy for prostate
    cancer from the second of two, independent, multi-center Phase 2
    clinical trials, which combined involved approximately 115 patients.
    Data from these two trials showed a median survival of 34.9 months and
    35.0 months, respectively, for the patients who received doses
    comparable to the Phase 3 dose. The results of the first trial were
    published in the July 1, 2007, issue of Clinical Cancer Research.
    These results exceeded the predicted survival of 22.5 months and 22.0
    months, respectively, as determined by a seven point patient disease
    characteristic nomogram. Results from both studies also compare
    favorably to the previously published median survival of 18.9 months
    for metastatic HRPC patients treated with Taxotere chemotherapy plus
    prednisone, the current standard of care. The company's ongoing
    Phase 3 program is designed to confirm a potential survival benefit and
    safety profile for GVAX immunotherapy for prostate cancer.

    -- Reported at the American Association for Cancer Research meeting in
    April 2007, immune response data from the company's two previously
    conducted Phase 2 clinical trials of GVAX immunotherapy for prostate
    cancer. Evaluation of antibody responses in patients with advanced
    prostate cancer from these studies shows that the GVAX cell-based
    immunotherapy induces antibody responses to a broad array of prostate
    cancer-associated antigens, including some not previously known to be
    associated with prostate cancer. In addition, the antibody responses to
    this non patient-specific product were predominantly patient-specific
    and unique from patient to patient, indicating the potential advantage
    of a cell-based multi-antigen product such as GVAX to generate the
    broadest and most relevant immune response.

    -- Announced three new clinical trials for GVAX immunotherapy for leukemia
    that are now under way in collaboration with the Johns Hopkins Sidney
    Kimmel Cancer Center. The new trials are based on encouraging results
    in an initial Phase 2 study of the product in patients with chronic
    myelogenous leukemia (CML) and include: a randomized Phase 2 trial in
    56 patients with CML who have persistent molecular evidence of disease
    following Gleevec(R) (imatinib) therapy that will compare the
    combination of GVAX plus continued Gleevec to the combination of
    interferon-alpha, GM-CSF plus continued Gleevec with respect to the
    levels of bcr-abl, a well-established marker of residual leukemia. In
    addition, there will be an extension study of the initial Phase 2 trial
    in patients with CML that will evaluate the efficacy of a second course
    of GVAX in patients who failed to achieve a sustained complete response
    and a Phase 1 trial in 18 patients with poor risk myelodysplastic
    syndrome.

    -- Announced follow-up data from a Phase 2 clinical trial of GVAX
    immunotherapy for pancreatic cancer that was conducted by the Johns
    Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients
    with operable pancreatic cancer who received GVAX after surgical
    resection of their tumor and adjuvant radiation and chemotherapy. The
    median overall survival for these patients was previously reported to
    be 26.8 months, a result which compares favorably to the 17 to
    22 months median survival results published from multiple studies in
    patients undergoing pancreatic cancer surgery and adjuvant therapy. Of
    note, 53 of the 60 patients were considered high risk, based on the
    unfavorable finding that their cancer had spread to regional lymph
    nodes. The new data included a median disease-free survival of
    approximately 16 months which compares favorably to the 13 months
    disease-free survival recently reported for gemcitabine adjuvant
    therapy.

    -- Announced follow-up data from the ongoing Phase 1 clinical trial in
    patients with advanced prostate cancer receiving GVAX immunotherapy for
    prostate cancer administered in combination with ipilimumab (MDX-010),
    a fully human anti-CTLA-4 antibody that is being jointly developed by
    Medarex and Bristol-Myers Squibb Company. The new data reported
    includes median follow-up of 18 months on the first 12 patients
    enrolled in the trial. Of the six patients who have received the two
    highest doses, antitumor activity has been observed in five patients,
    including prostate-specific antigen (PSA) declines of greater than
    50 percent that were maintained in four of these patients for at least
    six months, with the longest response to date at approximately
    16 months. Clinical evidence of antitumor activity has been observed
    in four of these five PSA responders, including complete resolution of
    multiple lesions on bone scan in two patients, and resolution of
    abdominal lymph node disease by CT scan and improvement in bone pain in
    one patient each. The five patients with PSA declines experienced
    either Grade 2 or 3 immune-mediated endocrine deficiencies similar in
    type to those previously reported with ipilimumab therapy, and were
    successfully treated with standard hormone replacement therapy and one
    patient who received the highest dose of ipilimumab developed a Grade 3
    dose-limiting pulmonary alveolitis that responded to steroid treatment.
    Immunomonitoring studies showed that the combination therapy enhanced T
    cell and dendritic cell activity, which was more pronounced at the
    higher dose levels.

    -- Raised gross proceeds of $60.0 million in a registered direct offering
    to institutional investors of 10.8 million shares of the company's
    common stock at $5.55 per share and warrants to purchase up to
    2.2 million shares of the company's common stock at a price of $7.18
    per share with selected institutional investors.

    -- Reached a favorable settlement with the IRS regarding the audit of the
    company's 2000 tax return. The settlement with the IRS was for
    $3.3 million in taxes and interest and resulted in a decrease in
    accrued income tax liabilities of $26.8 million.


    Cell Genesys will host its quarterly conference call at 2:00 p.m. PST on Tuesday, August 7, 2007, to discuss events that occurred during the second quarter of 2007. Investors may listen to the webcast of the conference call live on Cell Genesys' website. Alternatively, investors may listen to a replay of the call by dialing 800-475-6701 from locations in the U.S. and 320-365-3844 from outside the U.S. The call-in replay will be available for at least 72 hours following the call. Please refer to reservation number 880320.

    About Cell Genesys

    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

    Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on March 1, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

    CONTACT:
    Susan Ferris
    Investor Relations
    650-266-3200

    -- FINANCIAL CHARTS TO FOLLOW --


    SELECTED CONSOLIDATED FINANCIAL INFORMATION

    CONSOLIDATED STATEMENTS OF OPERATIONS DATA
    (unaudited, in thousands, except per share data)

    Three months ended Six months ended
    June 30, June 30,
    2007 2006 2007 2006

    Revenue $3 $1,046 $1,276 $1,222
    Operating expenses:
    Research and development 25,030 23,203 49,045 48,517
    General and administrative 4,782 4,268 10,027 9,296
    Total operating expenses 29,812 27,471 59,072 57,813
    Loss from operations (29,809) (26,425) (57,796) (56,591)
    Other income (expense):
    Gain on sale of Abgenix,
    Inc. common stock - - - 62,677
    Gain on sale of property
    and equipment 1,381 9 1,384 9
    Interest and other income 2,201 1,756 4,120 3,316
    Interest expense (2,582) (2,622) (5,181) (5,244)
    Income (loss) before income
    taxes (28,809) (27,282) (57,473) 4,167
    Income tax benefit (provision) 26,918 (610) 26,133 (28,045)
    Net loss $(1,891) $(27,892) $(31,340) $(23,878)

    Basic and diluted net loss
    per common share $(0.03) $(0.60) $(0.48) $(0.52)
    Weighted average shares of
    common stock outstanding -
    basic and diluted 71,171 46,629 65,939 46,127


    CONSOLIDATED BALANCE SHEET DATA
    (in thousands) June 30, December 31,
    2007 2006
    (unaudited) Note 1
    Cash, cash equivalents and short-term
    investments, including restricted cash $171,079 $154,074
    Prepaid expenses and other current assets 3,535 3,481
    Property and equipment, net 123,237 129,643
    Unamortized debt issuance costs and other assets 3,550 3,969

    Total assets $301,401 $291,167

    Other current liabilities $16,496 $15,904
    Current portion of accrued income taxes - 35,410
    Other liabilities 3,150 2,851
    Non-current portion of accrued income taxes 5,947 -
    Non-current portion of capital lease obligation 47,588 48,475
    Convertible senior notes 145,000 145,000
    Stockholders' equity 83,220 43,527

    Total liabilities and stockholders' equity $301,401 $291,167

    Note 1. Derived from audited financial statements.

    SOURCE Cell Genesys, Inc.
    08/07/2007
    CONTACT: Susan Ferris, Investor Relations of Cell Genesys, Inc.,
    +1-650-266-3200
    Web site: http://www.cellgenesys.com
    (CEGE)




    About Us | Product Progress | Patient Information | Investor's Corner | Career Opportunities
    ©2006 Cell Genesys, Inc. | Site Design: Heiney & Craig, Inc. | Home | Search
    Avatar
    asics01
    schrieb am 04.09.07 20:52:35
    Beitrag Nr. 24 (31.390.581)
    Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
    SOUTH SAN FRANCISCO, Calif., Sept 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Genesys, Inc. (Nasdaq: CEGE), today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the Bear Stearns 20th Annual Healthcare Conference in New York City on Tuesday, September 11, 2007, at 2:00 p.m. ET.
    A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

    Contact:

    Susan Ferris
    Investor Relations
    650-266-3200


    SOURCE Cell Genesys, Inc.

    http://www.cellgenesys.com




    About Us | Product Progress | Patient Information | Investor's Corner | Career Opportunities
    ©2006 Cell Genesys, Inc. | Site Design: Heiney & Craig, Inc. | Home | Search | Contact Us
    Avatar
    asics01
    schrieb am 31.10.07 20:12:17
    Beitrag Nr. 25 (32.224.106)
    Cell Genesys to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
    SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE), today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the Rodman and Renshaw 9th Annual Healthcare Conference in New York City on Tuesday, November 6, 2007, at 5:05 p.m. ET.

    A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

    Contact:

    Susan Ferris
    Investor Relations
    650-266-3200

    SOURCE Cell Genesys, Inc.
    10/30/2007
    CONTACT: Susan Ferris, Investor Relations of Cell Genesys, Inc.,
    +1-650-266-3200
    /Web site: http://www.cellgenesys.com
    (CEGE)
    dendreon und jetzt gpc gescheitert,jetzt wollen wir mal hoffen dass cege mehr erfolg mit GVAX gegen prostatakrebs hat.
    Avatar
    Ville7
    schrieb am 07.11.07 09:49:57
    Beitrag Nr. 26 (32.320.395)
    Mein Zielkurs "unter 3 USD" ist erreicht und somit melde ich meine erste Positionierung.

    Cell Genesys ist eine der Hoffnungen im Bereich Immunisierungstherapie gegen Krebs.

    Phase II Ergebnisse von GVAX in HRPC (hormonresistentem Prostatakrebs) waren hervorragende mehr als 12 Monate besser als der Standard of Care: Taxotere. In zwei Phase II Studien in der höchsten Dosierungsgruppe jeweils ca. 35 Monate.

    Aktuell werden zwei Phase III Studien durchgeführt, eine 1st line Vergleich gegen Taxotere und die zweite in Kombination mit Taxotere gegen Taxotere alleine. Studie 1 hat Patientenaufnahme schon abgeschlossen, Studie 2 wird dies Ende 2008, Anfang 2009 tun.

    Phase I Ergebnisse von GVAX in HRPC in Verbindung mit MEDX-010 (ipilimumab) sind mit 80% Responserate auch sehr ermutigend.

    GVAX zeigte zudem Wirkung in Leukämien und Bauchspeicheldrüsenkrebs, womöglich wird die Plattform in allen Krebsarten getestet und eventuell wirksam sein können.

    Vergleich zu Dendreon:
    Marktkapitalisierung DNDN: 700 Mio USD
    Marktkapitalisierung CEGE: 200 Mio USD

    Cash DNDN: 135 Mio USD
    Cash CEGE: 160 Mio USD

    Cashburn ungefähr gleich und Endergebnisse der Studien ungefähr zur selben Zeit erwartet (Endpunkt Overall Survival). Allerdings hat DNDN den Vorteil, bei positiven Interimsdaten schon Zulassung beantragen zu können (Absprache mit FDA).

    In der Technologie von CEGE sehe ich zudem Vorteile, es ist keine patientenspezifische teure Behandlung nötig wie bei Provenge, es handelt sich um ein vorgefertigtes Vaccine, daher weit höheres Vermaktungspotential.
    Avatar
    Ville7
    schrieb am 07.11.07 10:17:01
    Beitrag Nr. 27 (32.320.902)
    [URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=2418960[/URL]
    [URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=2418960[/URL]

    Weiterer Nachkauf nach Bodenbildung, sofern der dann mögliche EK mindestens 10% kleiner ist als mein heutiger EK.
    Avatar
    Ville7
    schrieb am 09.11.07 19:30:45
    Beitrag Nr. 28 (32.366.592)
    Avatar
    asics01
    schrieb am 09.11.07 19:59:20
    Beitrag Nr. 29 (32.367.013)
    Cell Genesys Downgrade


    Rating-Update:
    New York (aktiencheck.de AG) - Die Analysten von Needham & Co stufen die Aktie von Cell Genesys (ISIN US1509211041/ WKN 888140) von "buy" auf "hold" zurück. (02.11.2007/ac/a/u)
    Analyse-Datum: 02.11.2007
    Avatar
    Ville7
    schrieb am 17.11.07 01:39:22
    Beitrag Nr. 30 (32.461.923)
    Avatar
    GuHu1
    schrieb am 12.12.07 21:17:40
    Beitrag Nr. 31 (32.745.671)
    rancherho, IV board:

    Recs: 6 A Brief Summary of CEGE for Anyone Interested
    1. IMO, a great way to understand the science and Method of Action of CEGE’s lead GVAX therapy in Hormone Resistant Prostate Cancer (HRPC) is to watch the video webcast of the presentation of Dr. Kristan Hege at: Bringing Therapeutic Cancer Vaccines and Immunotherapies Through Development to Licensure (Day 1) Thursday, February 08, 2007 Begin at Time: 56 minutes. The first few minutes and slides in her presentation are particularly informative since they explain why just infusing irradiated prostate cancer cells alone, or in combination with recombinant GM-CSF doesn’t work (see the 21 day murine slides) while irradiated cancer cell lines expressing GM-CSF recruit and prime CD11c marked dendritic cells. The GVAX method of activating dendritic cells in vivo is somewhat akin to the fusion protein “cassette technology” linking a target antigen to GM-CSF, which DNDN uses to mature dendritic cells ex vivo. http://videocast.nih.gov/PastEvents.asp?c=1&s=21

    2. The agenda for all the FDA / NCI Workshop presentations is at: https://cms.palladianpartners.com/cms/1156354418/materials/f…


    3. Since then, a report on Phase 2 has been published in Clinical Cancer Research at: http://clincancerres.aacrjournals.org/cgi/content/abstract/1… CEGE has reported since then in September that in Ph2 trials, the high dose GVAX patients taking chemotherapy after GVAX (9 of 13 docetaxel) who had median survival >35.2 months in 4/07 had still not reached median survival.

    4. As Rr. Hege described, GVAX in AIPC is an allogenic cancer vaccine that uses two prostate cancer cell lines, genetically engineered to express GM-CSF and irradiated so that they cannot proliferate when infused into patients. The 600 patient Vital-1 Phase 3 trial with the endpoint of survival in asymptomatic AIPC/HRPC began enrollment in July 2004 and was been fully enrolled as of July. It compares GVAX to Taxotere, the standard of care. GVAX patients may subsequently take Taxotere, but must then discontinue further GVAX. Taxotere control patients can not, however, take GVAX.TheVital-1 interim look that is triggered by a pre-specified number of deaths is expected in 1H08, with the final look sometime in 2009. CEGE has a FDA Special Protocol Assessment (SPA) that will allow them to file a BLA if Vital 1 hits its statistical targets at either the interim or final look. The asymptomatic subgroup in the Taxotere TAX327 Ph3 pivotal trial had a median survival time of 23 months. The median survival of the Ph2 GVAX patients in the two trials taking the same high dose as is being used in all Ph3 trials was 34.9 and 35.0 months.

    5. The 600 patient Vital-2 trial in symptomatic AIPC/HRPC with the endpoint of survival began enrollment in July 2005. It compares GVAX plus Taxotere to GVAX alone. CEGE announced in a recent CC that it expects the interim look in early 2009 about the same time that it anticipates full enrollment. The symptomatic subgroup in the Taxotere TAX 327 Ph3 trial had a median survival of 16 months. This suggests that the trial is about half enrolled now. CEGE has stated that this trial has also has a SPA which will allow filing a BLA if statistical targets are met.

    6. Dosing in Vital 1 and Vital 2 is as follows:

    Patients in Vital-1 can take Chemo after 24 weeks of GVAX treatments, but once they start a non-GVAX procedure they will not be allowed to return to GVAX.

    Vital-1 trial:
    ARM 1: Initial cancer immunotherapy treatment is 13 bi-weekly injections over 24 weeks, followed by monthly cancer immunotherapy injections for life or until a new treatment for prostate cancer begins.

    ARM 2: Taxotere administered every 21 days and prednisone daily for 9 cycles.

    Vital-2 trial:
    Arm 1: Cancer immunotherapy injections in combination with Taxotere every 21 days over 10 cycles followed by monthly cancer immunotherapy injections alone for life or until a new treatment for prostate cancer begins.

    Arm 2: Taxotere administered every 21 days and prednisone daily for 10 cycles.

    7. John Hopkins is enrolling a Ph2 trial in HER2/neu breast cancer (open video) in combination with Herceptin” http://wjz.com/local/breast.cancer.vaccine.2.568678.html
    http://www.clinicaltrials.gov/ct2/show/NCT00399529?term=brea…

    8. Pancreatic Cancer: Phase 2 data; booster GVAX recommended in for further study. http://media.corporate-ir.net/media_files/IROL/98/98399/2007…

    9. Leukemia: Ph1 data given when Gleevec begins to fail: http://media.corporate-ir.net/media_files/IROL/98/98399/ASCO…

    10. CEGE also announced that they expect to report further in 2008 on their oncolytic virus program in bladder cancer as well as further updates on their early trial combining GVAX in AIPC with MDX-010 at CTLA blocker. http://media.corporate-ir.net/media_files/IROL/98/98399/2007…

    11. Recent webcasts: http://phx.corporate-ir.net/phoenix.zhtml?c=98399&p=irol-web…

    12. Infrastructure: The CEGE CEO, Dr. Sherwin, also reported in a recent CC that CEGE built a cGMP GVAX production facility sufficient to launch commercial production at a cost of “north of $50 million. Although the facility will not be inspected by the FDA on a FDA preapproval cGMP inspection, the State of California inspects the facility every year.

    IMO, CEGE's GVAX for AIPC and DNDN's Provenge, the efficacy of each significantly enhanced when used in combination with Taxotere, will become the first cellular cancer immunotherapies / vaccines that the FDA will approve. Given preparation of BLAs and FDA review cycles, this will probably occur during 2009. Their use in combination might also become commonplace one day. All JMHO.
    Avatar
    asics01
    schrieb am 14.01.08 19:44:19
    Beitrag Nr. 32 (33.045.191)
    Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
    Conference Call Scheduled for 10:00 a.m. ET Today
    SOUTH SAN FRANCISCO, Calif., Jan 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue. This event-driven interim analysis was designed to determine whether the study should continue to completion and took place in the time frame originally estimated. As is customary to preserve study blinding, the IDMC provided no information to the company other than the recommendation to continue the trial.
    "The IDMC's recommendation to continue with the VITAL-1 trial represents an important step forward in the Phase 3 development of GVAX immunotherapy for prostate cancer and in our effort to make this product available as a new treatment option for men with prostate cancer," stated Robert Dow, MBChB, chief medical officer of Cell Genesys. "Moreover, we can currently estimate that we will reach the required number of events needed to conduct the final analysis in the second half of 2009."

    VITAL-1 is a multi-center, randomized, controlled Phase 3 clinical trial designed to compare GVAX cancer immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus prednisone in hormone refractory prostate cancer (HRPC) patients with metastatic disease who are asymptomatic with respect to cancer- related pain. The primary endpoint of the trial is an improvement in survival. VITAL-1 was initiated in July 2004 and completed recruitment of 626 patients in July 2007. Patients were enrolled at approximately 130 sites in North America and Europe.

    The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

    The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

    About GVAX Cancer Immunotherapies

    GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX immunotherapy for prostate cancer in its bioreactor manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product during commercialization.

    Conference Call and Webcast

    Members of the Cell Genesys management team will host a conference call today, Monday, January 14 at 10:00 a.m. ET to discuss today's announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, http://www.cellgenesys.com. Alternatively, investors may listen to a replay of the call by dialing 800-475-6701 from locations in the United States and 320-365-3844 from outside the United States. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 907247.

    About Cell Genesys

    Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.

    Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results, analysis, and timing of VITAL-1 and VITAL-2 and other clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competitive technologies and products, patents, the need for and reliance on partnerships with third parties, and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's reports on Form 10-Q, 10-K, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

    Susan Ferris
    Investor Relations
    650-266-3200



    SOURCE Cell Genesys, Inc.

    http://www.cellgenesys.com
    Avatar
    asics01
    schrieb am 20.01.08 11:35:04
    Beitrag Nr. 33 (33.107.789)
    Those who believe investing is simply a matter of evaluating the bottom line have obviously not examined the fundamentals of too many biotech corporations. Many emerging biotech firms are years away from actual production, and have horrific balance sheets. That does not mean potential investors should shy away from them altogether, but they really need to understand the story and how likely it is that the company will deliver the goods.



    Just like panning for gold or drilling for oil, what these companies do offer is hope. In the case of Cell Genesys (CEGE) it is the hope for a cure to prostate cancer, the second-deadliest form of cancer among men.

    While CEGE focuses on a variety of different cancers and treatment options, it is the company's GVAX immunotherapy for prostate cancer that is invoking memories of Louis Pasteur.

    GVAX immunotherapy for prostate cancer is, in essence, a vaccine designed to enlist the body's own immune system to ward off unhealthy, or cancerous, cells. And clinical trials seem to suggest that GVAX has at least landed some early punches in the fight.

    In a recent Phase-II trial consisting of 80 Hormone Refractory Prostate Cancer [HRPC] patients, the survival time for the 22 who were administered the highest GVAX dosage is expected to exceed 29.1 months — significantly better than the 19.3 months achieved by Taxotere® (currently the best option for treating HRPC) in a similar, albeit larger, trial.

    In fact, Cell Genesys is so optimistic about GVAX as a remedy for prostate cancer that the company asked for and was granted Fast Track status by the FDA in May of 2006. A Fast Track designation helps to expedite the review process and Biologics License Applications (BLAs) for potential life-saving drugs and procedures.

    Cell Genesys is currently conducting two Phase-III trials of GVAX immunotherapy for prostate cancer.

    The first (VITAL-1) began in July 2004 and compares GVAX to Taxotere® chemotherapy administered with prednisone (an immunosuppressant), while the second (VITAL-2) commenced in June 2005 and compares GVAX plus Taxotere® to Taxotere® plus prednisone.

    If those trials go well, all that red ink may turn black — and lives could be saved or prolonged in the process.

    Not such a bad investment, perhaps.

    irgendwann werden sich hier hoffentlich die shorties die finger gewaltig verbrennen.
    Avatar
    GuHu1
    schrieb am 27.01.08 21:00:06
    Beitrag Nr. 34 (33.185.551)
    ansichten IV board, rancherho:

    Parsing CEGE's Vital 1 Interim Results

    From a comment and response on the Yahoo MB: >>2. The date for the final endpoint was not updated after the interim - it is still the guess from 2004!<<
    I don't think that is accurate. Sherwin spoke of delayed efficacy for the GVAX immunotherapy arm. Based on the Taxotere after Provenge immunotherapy data and the fact that Vital 1 allows Taxotere use in the GVAX arm, which also stops GVAX boosters (unfortunately IMO), the chances are that, as with Provenge, high dose GVAX alone might be able to show a median survival in the same range as the 2.4 month increase in median survival that Taxotere demonstrated in its pivotal TAX 327 clinical trial, but bettering it by 33% or more, even with high dosing, would be extraordinary. OTOH, IMO, there is a real possibility that the increase in median survival for experimental arm patients taking Taxotere after high dose GVAX could exceed the overall 35 months that high dose GVAX Ph2 patients demonstrated, since a maximum of 9 of 34 of those Ph2 patients took a subsequent taxane. It is also interesting to note that two of the lead GVAX investigators who coauthored the Ph2 studies, Drs. Small and Higano, were also lead investigators for the Provenge Ph2 studies and are well aware of the critical importance of subsequent Taxotere.

    So where does that leave the GVAX Vital 1 interim? One possible assumption might be that the median survival of the Taxotere control arm and the experimental patients who did not subsequently crossover to Taxotere were approximately equal. If the Taxotere control arm event rate was significantly greater than the experimental GVAX arm event rate, Vital 1 would have been stopped on safety and ethical grounds. If the treatment effect of the combination therapy is significantly greater than either GVAX or Taxotere alone, it is likely that the event rate for that subgroup in the experimental arm would begin a rapid decline in comparison to both the Taxotere control arm and the GVAX only subgroup in the experimental arm. Overall, the survival curves for the composite GVAX experimental arm (GVAX alone and GVAX + Taxotere) would flatten out its downward slope relative to the Taxotere (only) control arm. How would GVAX know this? My guess is that the significance of Dr. Petrylak’s November 2006 analysis of the importance of Taxotere after Provenge, which would be quite familiar to Drs. Small and Higano, and was supported by data from the small number of Ph 2 GVAX high dose patients subsequently receiving Taxotere, and the Vital 1 protocol allowing subsequent Taxotere in the GVAX experimental arm, was brought to the attention of all GVAX Vital 1 clinical investigators due to its potential significance for patient care and possible ethical implications. However, the IDMB would watch such a permissive operating hypothesis closely to assure that the safety and efficacy of any use of the GVAX plus Taxotere combination therapy was not trending in the wrong direction. CEGE would see any requirement for booster GVAX fall-off since the protocol requires that to start Taxotere, but that could also be a function of a patient’s choice or death. However, I believe that the IDMB could inform all Vital 1 clinical investigators and CEGE, without revealing any statistical information or breaking data blinding, that combination GVAX + Taxotere subgroup data suggested that it was not harmful to patients and could be beneficial. As the percentage of experimental arm patients taking the combination therapy increases, the experimental arm composite event rate would decline, explaining why it will take at least 2 years from the 7/07 completion of Vital 1 enrollment and 18 months after the assumed 200 event interim for 200 additional events to occur among the remaining 426 enrollees. Overall, this would explain why Sherwin said he was encouraged by the interim, even though he did not receive any statistical data.

    Finally the use of the Fleming O’Brien method of allocating an alpha (p value) at an interim point, which Sherwin indicated is what was used, is apparently one of the most conservative methods (suggesting, perhaps a p value =<.005). The delayed response of GVAX plus Taxotere would make this now seem sensible (although it would have been pre-specified before enrollment began in July 2004 and the synergistic effect would have been known.) For the sake of AIPC patients, I hope that DNDN’s Provenge, which will likely have a higher allocated p value at its interim, has positive enough interim data to re-file its BLA when it matures, which they project will occur in mid 2H08. If not, CEGE’s GVAX will likely become the first therapeutic cancer vaccine to receive FDA approval. All JMHO.


    http://www1.investorvillage.com/smbd.asp?mb=247&mn=257&pt=ms…
    Avatar
    asics01
    schrieb am 27.01.08 22:18:23
    Beitrag Nr. 35 (33.185.956)
    und trotz allem wird der kurs auf teufel komm raus runtergeprügelt:mad::mad:
    Avatar
    GuHu1
    schrieb am 27.01.08 23:53:32
    Beitrag Nr. 36 (33.186.439)
    Antwort auf Beitrag Nr.: 33.185.956 von asics01 am 27.01.08 22:18:23yep, bei beiden werten. :rolleyes:
    Avatar
    asics01
    schrieb am 28.01.08 09:29:10
    Beitrag Nr. 37 (33.187.618)
    Antwort auf Beitrag Nr.: 33.186.439 von GuHu1 am 27.01.08 23:53:32meinst du die schaffen es bis 2009 GVAX durchzubringen (wenn alles normal läuft)???
    asics
    Avatar
    GuHu1
    schrieb am 31.01.08 00:10:05
    Beitrag Nr. 38 (33.221.434)
    na du stellst mir fragen, da ich weiterhin bei dndn investiert bin und auch bleibe, ist cege einer der am weitesten fortgeschrittesten konkurrenten.

    ich denke es wird für beide werte schwer.
    die fda würde hier einen schritt machen der intern (scheinbar) auf hartnäckigen widerstand stößt. ich lasse bewußt daten und ergebnisse außen vor.
    schau dir die vorgehensweise beim anbau von gen manipuliertem mais in D an, ich persönlich ziehe hier den idiologischen vergleich.

    werde aber ein scharfes auge auf cege haben!

    alles nur meine persönliche meinung. ;)
    Avatar
    asics01
    schrieb am 31.01.08 08:54:30
    Beitrag Nr. 39 (33.222.299)
    Antwort auf Beitrag Nr.: 33.221.434 von GuHu1 am 31.01.08 00:10:05ich wollte doch nur einen tipp von dir.die zwischenergebnisse von GVAX sind bisher top, wenn die ergebnisse der dritten phase (die irgendwann dieses jahr kommen sollen), genauso gut sind wo soll dann das problem der FDA sein???ein zweites PROVEVNGE seitens der FDA wird es sicher nicht mehr geben.
    vielleicht ist GVAX besser als PROVENGE, oder andersrum oder alle beide nichts oder was weiß ich:confused::confused::confused:
    Avatar
    GuHu1
    schrieb am 31.01.08 21:04:55
    Beitrag Nr. 40 (33.231.760)
    Antwort auf Beitrag Nr.: 33.222.299 von asics01 am 31.01.08 08:54:30Hi asics,
    ich hoffe du hast mein posting nicht falsch verstanden, wollte dich nicht angreifen oder so.
    wollte damit nur sagen, dass ich die chance für cege`s GVAX nicht höher einschätze wie bei dndn`s provenge.
    ob GVAX besser arbeitet als Provenge, wer weiß, hatten viele auch bei gpc´s satra angenommen.
    wie schief man liegen kann zeigt uns das beispiel von GPC.
    aus dem grund bin ich mit derlei aussagen auch extrem vorsichtig.

    so blöd wie es klingt, dndn könnte eine art wegbereiter für cege werden, \"könnte\".
    fallen die interimsdaten zu provenge negativ aus bzw. die beendigung d. laufenden studie 9902b wird voraussetzung für eine provenge zulassung, dann neige ich zur ansicht des IV user rancherho.

    ....I hope that DNDN’s Provenge, which will likely have a higher allocated p value at its interim, has positive enough interim data to re-file its BLA when it matures, which they project will occur in mid 2H08. If not, CEGE’s GVAX will likely become the first therapeutic cancer vaccine to receive FDA approval.

    ich wills nicht beschreien aber ( ipilimumab: MDX-010 ) ist bei metastatic melanoma (monotherapie) an den primären endpunkten gescheitert. :rolleyes:

    wenn mich nicht alles täuscht ist MDX-010 auch grundlage bei cege`s GVAX.
    gleich im nachgang, schon klar das das ein anderes paar schuhe ist, es geht mir dabei um die tendenz!

    trotz dem bin ich auch am überlegen event. die erste kleinere position aufzubauen.

    grüße guhu ;)
    Avatar
    GuHu1
    schrieb am 31.01.08 22:17:35
    Beitrag Nr. 41 (33.232.750)
    http://www.medmix.at/set1.php?open=/artikel/515content.php

    Provenge®:
    Die therapeutische Prostatakrebsvakzine ist in den letzten Zügen der klinischen Entwicklung, dessen wichtigster Bestandteil das Prostata-spezifische Antigen (PSA) ist. Der Impfstoff könnte vor allem auch in früheren Stadien der Erkrankung zum Einsatz zu kommen.
    Die individualisierte Provenge®-Therapie besteht aus gentechnisch hergestelltem PSA und patienteneigenen Immunzellen: Dabei werden dendritische Zellen aus dem Blut des Patienten isoliert und nach ihrer Kopplung mit rekombinantem PSA zurück in den Patienten transferiert. Die so aktivierten dendritischen Zellen aktivieren ihrerseits T-Zellen, welche die Tumorzellen, die das Antigen tragen, attackieren und zerstören sollen.
    Nach Gabe von Provenge® konnte entweder ein Absinken der PSA-Konzentration oder aber die Verkleinerung des Tumors beobachtet werden. Der Überlebenszeitraum, der mit Provenge behandelten Patienten, konnte mehr als verdoppelt werden.

    GVAX®-Technologie:
    Die GVAX®-Technologie wird derzeit beim Prostatakarzinom, dem Lungenkarzinom, dem Pankreaskarzinom sowie bei Krebserkrankungen des Blutes – wie etwa der Leukämie und den Myelomen – untersucht. Die Daten einer Phase I/II-Studie bei Lungenkrebs wurden heuer in der renommierten Fachzeitschrift »Journal of the National Cancer Institute« vorgestellt und erörtert. Weiters laufen Phase-II-Studien beim broncho-alveolarem Karzinom, einem Subtyp des nicht-kleinzelligen Lungenkarzinoms und beim Pankreaskarzinom. Die Wirkung von GVAX® beim Prostatakarzinom in Kombination mit Chemotherapie wird demnächst in einer Phase-III-Studie untersucht.
    GVAX® unterscheidet sich von den meisten therapeutischen Vakzinen dadurch, dass es – mit Ausnahme gegen das Lungenkarzinom – nicht-patientenspezifisch ist. Die unspezifischen GVAX®-Impfstoffe bestehen aus bestrahlten und genetisch modifizierten Krebszellen, die durch die genetischen Modifikationen dazu in der Lage sind, GM-CSF (Granulozyten-Makrophagen stimulierender Faktor) herzustellen. Die Technologie zielt auf einen universellen Ansatz, da GM-CSF ein Hormon ist, das die körpereigne Immunabwehr ganz generell ankurbelt. Unspezifische Impfstoffe haben gegenüber den individualisierten Produkten den Vorteil, dass sie sich leicht in Massenproduktion herstellen lassen. Obwohl die Tumorzellen in GVAX® nicht vom jeweiligen Patienten stammen, konnte die Impfung bei allen bisher getesteten Krebsarten eine Aktivität des Immunsystems hervorrufen.

    http://www.ukaachen.de/go/show?ID=5381454&ALTNAVID=5113065&D…

    http://seekingalpha.com/article/34661-cell-genesys-the-promi…

    http://www.ft.com/cms/s/2/e4e6a040-4f8f-11dc-b485-0000779fd2…
    Avatar
    GuHu1
    schrieb am 01.02.08 23:44:51
    Beitrag Nr. 42 (33.245.909)
    good post on cege

    http://www1.investorvillage.com/smbd.asp?mb=247&mn=249&pt=ms…


    Horne, who turns 74 on Wednesday, remains vibrant and healthy-looking. She travels between homes in New York and California, teaching at Carnegie Hall and various colleges and running a summer school and festival in Santa Barbara, Calif.

    The week before her birthday, Horne was at Baltimore's Johns Hopkins Sidney Kimmel Cancer Center, getting another dose of a new cancer vaccine that has so far been administered to only about 200 people.

    Horne began receiving the injections of lab-grown pancreatic cancer cells in early 2007, after surgery to remove the tumor. The vaccine has been genetically modified with an immune-boosting gene to tackle any lingering malignant cells.

    She was injected every two months for a half year, and is now scheduled to get additional doses twice a year.

    "Essentially, the vaccine teaches the immune system to recognize those pancreas cancer cells as being foreign and attack them specifically," says Dr. Daniel Laheru, a Johns Hopkins oncologist leading the study. "Her most important treatment was the surgery, but we hope the vaccine is additional insurance against recurrence."
    Avatar
    GuHu1
    schrieb am 11.02.08 00:20:45
    Beitrag Nr. 43 (33.326.016)
    quele IV: :rolleyes:

    Recs: 0 Insiders
    DNDN - % of Shares Held by All Insider and 5% Owners: 2%
    CEGE - % of Shares Held by All Insider and 5% Owners: 10%
    GNVC - % of Shares Held by All Insider and 5% Owners: 16%

    http://finance.yahoo.com/q/mh?s=DNDN
    http://finance.yahoo.com/q/mh?s=cege
    http://finance.yahoo.com/q/mh?s=gnvc

    I find this disturbing. All that optimism about Provenge and only 2% of shares held by insiders. The executives from other competing companies seems to have more confidence in the outcome of theirs PC clinical trials. Would anybody who is knowledgeable in the subject have a comment or an explanation for this?
    Thanks
    Avatar
    GuHu1
    schrieb am 14.02.08 23:08:41
    Beitrag Nr. 44 (33.375.482)
    ist schon eigentümlich der zusammenhang cege zu dndn.

    http://www.forbes.com/2008/02/14/dendreon-prostrate-cancer-m…

    ...........Pantginis believes the competition from Cell Genesys (nasdaq: CEGE - news - people )’ GVAX prostrate cancer vaccine will not allow Dendreon to get a sizable market share. If both drugs get approved, Pantginis says that GVAX will win out because of logistics, cost, and efficacy. Cell Genesys’ shares jumped 4.8%, or 9 cents, to $1.98 in afternoon trading on Thursday.

    das IF würde ich erst mal fett unterstreichen (gilt für beide).
    Avatar
    Larry_1
    schrieb am 15.02.08 20:52:59
    Beitrag Nr. 45 (33.386.344)
    Antwort auf Beitrag Nr.: 33.375.482 von GuHu1 am 14.02.08 23:08:41das IF zeigt eine Klasse Wirkung :kiss:
    ich habs mal fett gemacht:D
    Avatar
    Larry_1
    schrieb am 15.02.08 21:20:31
    Beitrag Nr. 46 (33.386.719)
    Antwort auf Beitrag Nr.: 33.386.344 von Larry_1 am 15.02.08 20:52:59FinanzNachrichten.de, 15.02.2008 14:34:00
    Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
    SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial in patients with metastatic, hormone refractory prostate cancer (HRPC). More than 400 patient-specific GVAX-induced antibody responses were identified in the sera of the treated patients by three different biochemical techniques confirming, as previously reported, that GVAX treatment results in a broad, multi-antigen immune response. An ongoing analysis of these GVAX-induced antibody responses has shown that at least two of the antibody responses are associated with patient survival, an association that is independent of the dose and number of treatments administered. These data will be presented today by Dr. Thomas Harding and colleagues from Cell Genesys at the American Society of Clinical Oncology's Genitourinary Cancer Symposium being held in San Francisco, California.

    Cell Genesys has previously reported the results of two multicenter Phase 2 trials of GVAX immunotherapy for prostate cancer in metastatic HRPC. The second of these two trials enrolled 80 patients. The serum of 65 patients (the total number for whom adequate sera were available) were examined to determine each patient's immune response to two specific antigens, HLA-A24 and FLJ14668, following GVAX treatment. Thirty-four of 65 patients demonstrated an FLJ14668-specific antibody immune response. These 34 patients had a median survival of 43 months, compared to a median survival of 21 months achieved by the patients who did not generate anti-FLJ14668 antibodies (p=0.002). Twenty-two of these 65 patients received a dose of GVAX immunotherapy for prostate cancer comparable to that being evaluated in ongoing Phase 3 clinical trials. Of these 22 patients, 16 patients (73 percent) mounted an immune response to FLJ14668. These 16 patients achieved a median survival of 44.9 months. As previously reported, the median survival for all 22 patients in this treatment group was 35.0 months. Finally, of the 58 patients who were HLA-A24 genotype negative and therefore potentially able to mount anti-HLA-A24 specific antibody responses, 30 patients were found to be anti-HLA-A24 antibody positive. These 30 patients had a median survival of 43 months, compared to a median survival of 18 months in the patients who did not generate anti-HLA-A24 antibodies (p=0.05). Importantly, the apparent associations between the presence of these two specific antibody responses and survival were shown by multivariate analysis to be independent of both dose and duration of treatment.

    "The findings being reported today indicate a potential association between two specific GVAX-induced antibody responses and patient survival, an association consistent with the proposed mechanism of action for this product. We look forward to expanding these findings in a prospective analysis of the sera of patients treated in our two randomized controlled Phase 3 trials," stated Peter K. Working, Ph.D., senior vice president of research and development at Cell Genesys. "Since GVAX immunotherapy for prostate cancer is a multi-antigen product that can induce a broad immune response, we believe we have a unique opportunity to identify the widest possible array of specific antibody responses that may be associated with clinical benefit."

    Cell Genesys is currently evaluating GVAX immunotherapy for prostate cancer in two Phase 3 multicenter, randomized, controlled clinical trials. VITAL-1, which is fully enrolled with 626 patients, is designed to compare GVAX cancer immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus prednisone in HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. An interim analysis of the trial was recently conducted by an independent data monitoring committee in the timeframe originally estimated and resulted in the recommendation to continue the trial. The company expects to have enough events to trigger the final analysis of VITAL-1 in the second half of 2009. VITAL-2, which the company expects to fully enroll with approximately 600 patients in the first half of 2009, is designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. The company expects to have enough events to trigger an interim analysis of VITAL-2 in the first half of 2009.
    Avatar
    Larry_1
    schrieb am 15.02.08 21:32:30
    Beitrag Nr. 47 (33.386.905)
    Cell Genesys Say's GVAX Increases Patience Survival [CEGE]

    2/15/2008 3:20:23 PM Friday, Cell Genesys, Inc. (CEGE), a biotechnology company, said that a phase 2 trial conducted on patients with metastatic, hormone refractory prostate cancer or HRPC identified that GVAX-induced antibody responses are associated with patient survival. The response was indicated as independent of the dose and number of treatments administered.

    GVAX cancer immunotherapies are non patient-specific investigational products for fighting prostrate cancer, pancreatic cancer, and leukemia.

    The South San Francisco, California-based Cell Genesys said that the more than 400 patient-specific GVAX-induced antibody responses identified in the sera of the treated patients, indicated GVAX treatments to have resulted in broad, multi-antigen immune response. An analysis showed at least two of the antibody responses as associated with patient survival.

    Cell Genesys has previously reported the results of two multicenter Phase 2 trials of GVAX immunotherapy for prostate cancer in metastatic HRPC. The second of these two trials enrolled 80 patients.

    Depending on the availability of the serum, the company noted that the trial examined 65 patient's immune response to two specific antigens HLA-A24 and FLJ14668, following GVAX treatment. Finally, 30 patients were found to be anti-HLA-A24 antibody positive, with a median survival of 43 months, compared to a median survival of 18 months in patients who did not generate anti-HLA-A24 antibodies.

    Twenty-two patients who received a dose of GVAX immunotherapy for prostate cancer comparable to that being evaluated in ongoing Phase 3 clinical trials. Of these, 16 patients achieved a median survival of 44.9 months.

    Further, the company noted that it is looking forward to expand these findings in a prospective analysis of the sera of patients treated in two randomized controlled Phase 3 trials.

    Cell Genesys is currently evaluating GVAX immunotherapy for prostate cancer in two Phase 3 multicenter, randomized, controlled clinical trials. VITAL-1, which is fully enrolled with 626 patients, is designed to compare GVAX cancer immunotherapy to Taxotere chemotherapy plus prednisone in HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. The company expects the final analysis of VITAL-1 in the second half of 2009.

    Also VITAL-2, which the company expects to have an interim analysis in the first half of 2009, also has improvement in survival as the primary endpoint.

    CEGE is currently trading at $2.4301, up $0.4601 or 23.36% on a volume of 4.16 million shares.
    Avatar
    Larry_1
    schrieb am 15.02.08 21:39:47
    Beitrag Nr. 48 (33.387.001)
    Wer beschätigt sich schon länger mit Cell Genesys, und kann

    interpretieren was diese Meldung für CEGE bedeutet, ich meine das

    evtl. Umsatzpotiental von GVAX wenn denn die Phase 3 erfolgreich

    beendet werden sollte.
    Avatar
    GuHu1
    schrieb am 15.02.08 21:59:53
    Beitrag Nr. 49 (33.387.324)
    Antwort auf Beitrag Nr.: 33.387.001 von Larry_1 am 15.02.08 21:39:47meinen glückwunsch zur news. ;)
    möglicherweise gibt sich ville einen ruck und versucht hier etwas klarheit reinzubringen.
    Avatar
    GuHu1
    schrieb am 15.02.08 22:14:26
    Beitrag Nr. 50 (33.387.481)
    Antwort auf Beitrag Nr.: 33.387.001 von Larry_1 am 15.02.08 21:39:47larry, versuchs mal mit dem link zum IV, Rancherho hat einen kommentar zur situation. ;)

    http://www1.investorvillage.com/smbd.asp?mb=971&mn=182711&pt…
    Avatar
    Larry_1
    schrieb am 16.02.08 12:09:09
    Beitrag Nr. 51 (33.390.735)
    Antwort auf Beitrag Nr.: 33.387.324 von GuHu1 am 15.02.08 21:59:53Danke für die Info und ein schönes Wochenende
    Avatar
    GuHu1
    schrieb am 17.02.08 01:10:59
    Beitrag Nr. 52 (33.393.776)
    Antwort auf Beitrag Nr.: 33.390.735 von Larry_1 am 16.02.08 12:09:09bitte immer gern, hab ja gesagt das ich auch ein auge auf cege habe. ;)

    http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2008/02/16/…
    Avatar
    Uptick08
    schrieb am 17.02.08 12:22:42
    Beitrag Nr. 53 (33.394.637)


    Ist das der Anfang oder eher Ende der story:rolleyes::keks:
    Avatar
    Larry_1
    schrieb am 19.02.08 20:46:44
    Beitrag Nr. 54 (33.415.954)
    Antwort auf Beitrag Nr.: 33.393.776 von GuHu1 am 17.02.08 01:10:59so, ich habe mich vorhin mal von meinem kompletten Bestand getrennt.
    Ich denke, das der Kurs wieder etwas runterkommt, dann werde ich wieder ordern
    so long
    :cool:
    Avatar
    GuHu1
    schrieb am 19.02.08 21:07:19
    Beitrag Nr. 55 (33.416.219)
    Antwort auf Beitrag Nr.: 33.394.637 von Uptick08 am 17.02.08 12:22:42
    Feb. 19, 2008, 12:43PM
    Cell Genesys Shares Continue Climb

    © 2008 The Associated Press

    NEW YORK — Shares of Cell Genesys Inc. continued climbing Tuesday, following last week's report showing its vaccine candidate helped prostate cancer patients live longer in a midstage study.

    The stock rose 48 cents, or 22 percent, to $2.88 in afternoon trading. On Friday, shares gained 19.7 percent after midstage study results were announced.

    "We continue to believe that Cell Genesys is undervalued and has not benefited from the continuous and striking positive clinical data flow to date," said Canaccord Adams analyst Joseph Pantginis, who reaffirmed a "Buy" rating with a $7.70 price target.

    On Friday, the company said its GVAX vaccine both invoked an immune response and extended the survival rate of those patients to 43 months, on average. Patients who didn't have an immune response lived for an average of 21 months.

    The Food and Drug Administration has yet to approve a cancer vaccine.

    Pantginis said the company seems to have accomplished a key goal of simulating the immune system to fight tumors. Also, the drug would likely beat out its competitor Provenge, being developed by Dendreon Corp., based on cost and effectiveness issues.

    "Regarding last week's immunological data from both companies, we believe Cell Genesys knocked it out of the park, showing a distinct correlation between specific antigens and survival," he said.

    Dendreon reported data showing a general immune response, he said. So far, study subjects taking Provenge have shown a median survival rate of 25.2 months while those taking GVAX have shown a 35 month survival rate, he noted.

    He also said that if current late-stage study data on Provenge, set for release in the second half of 2008, turns out to be negative, the company may not be able to recover. Meanwhile, Cell Genesys already has the manufacturing capacity in place for GVAX, while Dendreon has been struggling.

    Shares of Dendreon fell 16 cents, or 2.8 percent, to $5.70.
    Avatar
    GuHu1
    schrieb am 21.02.08 23:18:03
    Beitrag Nr. 56 (33.442.499)
    Antwort auf Beitrag Nr.: 33.415.954 von Larry_1 am 19.02.08 20:46:44respekt larry, wenn das nicht :cool: war dann weiß ichs auch nicht.;)
    Avatar
    Larry_1
    schrieb am 23.02.08 21:44:05
    Beitrag Nr. 57 (33.457.156)
    Antwort auf Beitrag Nr.: 33.442.499 von GuHu1 am 21.02.08 23:18:03ja, diese Woche war bei mir geballt positiv.
    Der absolute Knaller war aber ENCYSIVE PHARMACEUTICALS :kiss:
    Ciao
    Avatar
    GuHu1
    schrieb am 07.03.08 23:57:18
    Beitrag Nr. 58 (33.585.497)
    nun ja, da sind wir schon fast wieder am ausgangspunkt der kurzen rally.
    noch mal mein respekt an larry, besser hättes er kaum treffen können. :cool:
    Avatar
    GuHu1
    schrieb am 25.03.08 19:09:23
    Beitrag Nr. 59 (33.722.826)
    Avatar
    GuHu1
    schrieb am 31.03.08 22:13:14
    Beitrag Nr. 60 (33.771.872)
    quelle IV:

    http://www.investorvillage.com/smbd.asp?mb=971&mn=190494&pt=…

    enesys, Inc. ("Cell Genesys") (CEGE) and Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502) today announced that the companies have formed a global alliance for the development and commercialization of GVAX immunotherapy for prostate cancer, Cell Genesys' lead product candidate currently in Phase 3 clinical development.
    Under the agreement, in exchange for exclusive worldwide commercial rights to GVAX immunotherapy for prostate cancer, Takeda will pay Cell Genesys an upfront payment of $50 million and additional milestone payments totaling up to $270 million relating to regulatory approval and commercialization of GVAX immunotherapy for prostate cancer in the United States, European Union and Japan. Takeda will pay Cell Genesys tiered, double-digit royalties based on net sales of GVAX immunotherapy for prostate cancer in the United States and flat double-digit royalties based on net sales of the product in all other regions. From this point forward, Takeda will pay for all external development costs associated with the ongoing Phase 3 clinical development of GVAX immunotherapy for prostate cancer and will also pay for all additional development costs and all commercialization costs. Cell Genesys will maintain responsibility for the worldwide manufacture and supply of the product and will retain rights to co-promote GVAX immunotherapy for prostate cancer in the United States.
    Avatar
    GuHu1
    schrieb am 04.04.08 16:10:30
    Beitrag Nr. 61 (33.811.103)
    Avatar
    Ville7
    schrieb am 14.04.08 08:27:14
    Beitrag Nr. 62 (33.876.958)
    Heute abend 22Uhr wird es spannend für MEDX und CEGE Aktionäre. Was gibt es neues zu GVAX+ipilimumab(MDX-010) beim AACR? Der Abstract wurde zurückgehalten um die Meldung in das AACR Presseprogramm mitaufzunehmen. Daher ist mit nicht unbedeutender News zu rechnen und in aller Regel nicht mit negativer!

    ------------------------------------------

    Abstract Number: 2538
    Session Title: Clinical Immunotherapy
    Presentation Title: Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer treated with GVAX immunotherapy for prostate cancer and ipilimumab
    Presentation Start/End Time: Monday, Apr 14, 2008, 1:25 PM - 1:40 PM
    Location: Room 30A-C, San Diego Convention Center
    Author Block: Saskia J.A.M. Santegoets, Alfons J.M. Van den Eertwegh, Sinead M. Lougheed, Anita G.M. Stam, Helen Gall, Petra E.T. Scholten, Mary B.E. Von Blomberg, Erik Hooijberg, Karin Jooss, Nathalie Sacks, Minh Nguyen, Thomas Harding, Thomas Harding, Kristen Hege, Israel Lowy, Winald R. Gerritsen, Rik J. Scheper, Tanja D. De Gruijl. VU University Medical Center, Amsterdam, The Netherlands, Cell Genesys Inc, San Francisco, CA, Medarex, Bloomsbury, NY
    Abstract 2538 has been selected for inclusion in the AACR’s Annual Meeting press program and is therefore embargoed until date and time of press briefing or scientific presentation, whichever comes first. The abstract is scheduled for scientific presentation and will be posted to this site at or after the following date and time: 4/14/2008 1:00 PM.
    Avatar
    Ville7
    schrieb am 14.05.08 09:32:17
    Beitrag Nr. 63 (34.087.996)
    Morgen gibts die ASCO ABstracts. Wie haben die 14 zusätzlichen Patienten der GVAX+MED-010 Studie abgeschnitten. Das ist die Studie mit den 5/6 PSA Responses und den 4/6 Responses.

    Kommentaren eines Arztes zufolge (ich habe den Link nicht mehr) könnte es nur eine zusätzliche Response aus 14 zusätzlichen Patienten gegeben haben. Das wäre natürlich enttäuschend.

    Ich lasse mich aber überraschen.
    Avatar
    GuHu1
    schrieb am 15.05.08 21:47:11
    Beitrag Nr. 64 (34.105.205)
    Avatar
    Ville7
    schrieb am 16.05.08 10:44:14
    Beitrag Nr. 65 (34.108.191)
    16 Patienten zusätzlich, 6 davon bisher vollständig behandelt. Bisher erst eine zusätzliche PSA Response, drei stabil. Leider muss man wahrscheinlich noch ein Jahr auf die vollständigen Daten der 16 Patienten der Expansion Gruppe warten. Sie werden allerdings erwartungsgemäß nicht so gut werden, wie die 5/6 PSA Responses der bisher höchsten Gruppe.

    --------------------------

    Background: A Phase 1 trial is underway to study GVAX immunotherapy for prostate cancer [GVAX immunotherapy (GVAX IT)] and ipilimumab (Ipi) in chemonaïve mHRPC patients (pts).

    Methods: Twelve pts were treated in a dose-escalation phase for 24 weeks (wks) with bi-weekly intradermal injections of GVAX IT and monthly Ipi. Pts were enrolled in cohorts of 3; each cohort received an escalating dose of Ipi: 0.3, 1, 3 or 5 mg/kg. Sixteen pts were then enrolled in an expansion cohort to be treated with GVAX IT and 3 mg/kg Ipi.

    Results:

    Escalation Cohort: Median follow-up of 12 pts is 21.2 months (m). Five of six pts at the higher Ipi doses (3 and 5 mg/kg) developed Grade 2 or 3 immune-related adverse events (irAEs), including Grade 2 or 3 hypophysitis and Grade 3 alveolitis. Late onset PSA responses (declines > 50%) were seen in these 5 pts with response durations of 6.7, 8.6, 9.5, 13.8 (on-going), and 23.1 m. Four of these pts had stable disease on bone scan for at least 12 m, and up to 21 m. Multiple tumor-reactive antibodies (abs) induced by treatment were identified by serologic analysis (SEREX), including abs to filamin B, PSMA and NY-ESO-1. Biopsies of injection sites showed T cell infiltration and Granzyme B expression; these T cells are being tested for antigen-specific lytic activity.

    Expansion Cohort: Sixteen pts were enrolled, 6 have completed treatment, 10 are on-going. Three pts have experienced irAEs of Grade 1 diarrhea, Grade 3 adrenal insufficiency, and a Grade 3 hepatitis that resolved with steroids. With median follow-up of 6.5 months in the 6 pts who have completed treatment, 1 pt had a PSA response (> 50% decline) and 3 obtained stable PSA, accompanied in one pt by pain relief and decrease in alkaline phosphatase. Conclusions: The GVAX IT and ipilimumab combination is active in mHRPC in this trial. IrAEs appear manageable and may correlate with anti-tumor activity. The maximum tolerated dose of the combination is not established. Follow-up on the 16 expansion cohort pts will provide data on safety, clinical activity and immunologic correlates.
    Avatar
    Uptick08
    schrieb am 23.07.08 09:51:14
    Beitrag Nr. 66 (34.566.767)
    Ein fast tot geglaubte Thread und Aktie...aber siehe dar:eek: CEGE lebt!



    Na leute, Trend erkannt ;)
    Avatar
    Uptick08
    schrieb am 23.07.08 09:54:04
    Beitrag Nr. 67 (34.566.789)
    Antwort auf Beitrag Nr.: 34.566.767 von Uptick08 am 23.07.08 09:51:14ach übrigens, laut die Experten stateside stehen wir hier auch am Anfang der neue Entwicklung



    and it's a real long way back up...:rolleyes::cool:
    Avatar
    asics01
    schrieb am 27.08.08 16:11:32
    Beitrag Nr. 68 (34.879.272)
    jetzt hat s CEGE erwischt -75 %

    Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer
    Conference Call Scheduled for 8:30 a.m. ET Today
    SOUTH SAN FRANCISCO, Calif., Aug 27, 2008 (BUSINESS WIRE) -- Cell Genesys, Inc. (Nasdaq:CEGE) today announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere(R) (docetaxel) to Taxotere plus prednisone in patients with advanced-stage prostate cancer. The Company ended the trial as recommended by its Independent Data Monitoring Committee (IDMC) which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study. To date, VITAL-2 enrolled 408 patients. The IDMC based its recommendation on 114 deaths of which 67 occurred in the GVAX plus Taxotere combination treatment arm and 47 deaths occurred in the Taxotere control arm. At this time, a specific cause for the imbalance in deaths has not been identified and the IDMC reported no new safety issues for GVAX when administered in combination with Taxotere. The Company plans to fully analyze the clinical data from these patients to attempt to understand the potential cause for the higher rate of deaths observed in the GVAX immunotherapy plus Taxotere combination arm, including an assessment of potential imbalances between the two arms of the study such as baseline characteristics and prognostic factors, as well as other treatment variables. In light of the IDMC's observation with respect to VITAL-2, the Company has requested that the IDMC perform a previously unspecified futility analysis of VITAL-1, the other Phase 3 clinical trial of GVAX immunotherapy for prostate cancer. The Company expects the results of the VITAL-1 futility analysis in approximately one month.
    "Patient safety is always our paramount concern and so we have immediately responded to the recommendation of the IDMC. We are currently notifying all participating clinical trial sites and regulatory agencies that enrollment of new patients into VITAL-2 has been suspended as has treatment with GVAX immunotherapy for prostate cancer of patients enrolled in the study," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "Notwithstanding this disappointing outcome, we would like to acknowledge the courage and commitment of the patients and physicians who have participated in this trial."

    Dr. Sherwin continued, "The observation in the VITAL-2 trial is very surprising to us, and we have therefore asked the IDMC to conduct a previously unplanned futility analysis of VITAL-1 in order to determine the overall prospects for our ongoing development program for this product. Moreover, with the cessation of VITAL-2, we expect to make commensurate adjustments to our business operations and we will provide further details regarding this in the near future. As a reminder, the company ended the second quarter of 2008 with $166 million in cash."

    VITAL-2 was a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in hormone-refractory prostate cancer (HRPC) patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial was an improvement in survival. VITAL-2 was initiated in June 2005 and to date had enrolled 408 patients at 115 clinical trial sites located in North America and the European Union. VITAL-1, the other Phase 3 clinical trial of GVAX immunotherapy for prostate cancer, is designed to compare GVAX cancer immunotherapy as a monotherapy to Taxotere chemotherapy plus prednisone in earlier stage HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. In 2007, the VITAL-1 trial completed enrollment with 626 patients. In January 2008, Cell Genesys announced that the IDMC had completed a pre-planned interim analysis for VITAL-1 and recommended that the study continue, providing no further information to the company other than the recommendation to continue the trial.

    Conference Call and Webcast

    Members of the Cell Genesys management team will host a conference call today, Wednesday, August 27, 2008, at 8:30 a.m. ET to discuss the IDMC's recommendation. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, www.cellgenesys.com. Alternatively, investors may listen to a replay of the call by dialing (800) 475-6701 from locations in the U.S. and (320) 365-3844 from outside the U.S. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 958709.

    About GVAX Immunotherapy for Prostate Cancer

    GVAX immunotherapy for prostate cancer is comprised of two prostate tumor cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine that plays a key role in stimulating the body's immune response, and then irradiated for safety. GVAX immunotherapy for prostate cancer is designed to be administered through intradermal injections on an outpatient basis.

    About Cell Genesys

    Cell Genesys (Nasdaq: CEGE) is focused on the development and commercialization of novel biological therapies for patients with cancer. The company's lead product platform is GVAX(R) immunotherapy for cancer, which holds the potential to treat multiple types of cancer including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, California, and has manufacturing operations in Hayward, California. For additional information, please visit the company's website at www.cellgenesys.com.

    Statements made herein about the company, other than statements of historical fact, including statements about the company's progress, results, findings, analysis and timing of clinical trials and preclinical programs, the timing of completion of and results from the VITAL-1 futility analysis discussed above and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competitive technologies and products, the need for and reliance on partnerships with third parties, and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's reports on Form 10-Q, 10-K, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

    SOURCE: Cell Genesys, Inc.

    Cell Genesys, Inc.
    Susan Ferris, 650-266-3200
    Investor Relations







    About Us | Product Progress | Patient Information | Investor's Corner | Career Opportunities
    ©2006 Cell Genesys, Inc. | Site Design: Heiney & Craig, Inc. | Home | Search | Contact Us
    Avatar
    Kurumba
    schrieb am 28.08.08 00:10:43
    Beitrag Nr. 69 (34.885.462)
    mannomann- bin ich froh, das ich die für 12 euro mit verlust vekauft habe
    Avatar
    grafbibi
    schrieb am 28.08.08 13:54:33
    Beitrag Nr. 70 (34.891.100)
    Antwort auf Beitrag Nr.: 34.885.462 von Kurumba am 28.08.08 00:10:43RT http://finance.google.com/finance?q=NASDAQ:CEGE


    Avatar
    grafbibi
    schrieb am 28.08.08 13:56:16
    Beitrag Nr. 71 (34.891.123)
    Antwort auf Beitrag Nr.: 34.891.100 von grafbibi am 28.08.08 13:54:33RT Kurse !!

    http://de.advfn.com/p.php?pid=qkquote&btn=s_ok&qkbtn=&qksymb…
    Avatar
    grafbibi
    schrieb am 28.08.08 14:01:54
    Beitrag Nr. 72 (34.891.222)
    Avatar
    grafbibi
    schrieb am 28.08.08 14:22:44
    Beitrag Nr. 73 (34.891.528)
    Avatar
    Larry_1
    schrieb am 28.08.08 17:19:56
    Beitrag Nr. 74 (34.894.908)
    Klasse Reaktion (für die, die nach dem gestrigen Crash eingestiegen sind) :kiss:
    Avatar
    Larry_1
    schrieb am 31.08.08 17:26:17
    Beitrag Nr. 75 (34.925.687)
    Meines Erachtens übertriebener Kursabschlag

    aktuelle Proktpipeline:
    http://www.cellgenesys.com/products.shtml

    Ist auf jeden Fall ein Einstieg bzw. Aufstockung wert
    :cool:
    Avatar
    Larry_1
    schrieb am 03.09.08 10:16:12
    Beitrag Nr. 76 (34.958.968)
    gestern nochmals ein übler Einbruch :(
    bin gespannt auf heute in USA :confused:
    Avatar
    asics01
    schrieb am 16.10.08 18:50:54
    Beitrag Nr. 77 (35.594.618)
    das wars dann wohl

    Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Based on Outcome of Futility Analysis and Reports Preliminary Analysis of VITAL-2 Trial Results
    Restructuring of Business Operations Implemented Conference Call Scheduled for 8:30 a.m. ET Today
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

    Cell Genesys, Inc. (Nasdaq:CEGE) today announced its decision to terminate the VITAL-1 Phase 3 clinical trial of GVAX immunotherapy in patients with asymptomatic metastatic hormone-refractory prostate cancer. The trial was fully enrolled in 2007 with 626 patients and compared GVAX immunotherapy to Taxotere(R) (docetaxel) chemotherapy plus prednisone. The Company terminated the trial based on the results of a previously unplanned futility analysis conducted by the study's Independent Data Monitoring Committee (IDMC) which indicated that the trial had less than a 30 percent chance of meeting its predefined primary endpoint of an improvement in survival.

    On August 27, 2008, Cell Genesys announced that it had requested the IDMC conduct a futility analysis of the VITAL-1 trial following the termination of VITAL-2, the Company's other Phase 3 trial of GVAX immunotherapy for prostate cancer. In view of the termination of both the VITAL-1 and VITAL-2 trials, the Company will place on hold the further development of GVAX immunotherapy for prostate cancer pending a review of the program with its collaborator, Takeda Pharmaceutical Co. Ltd. As a result of these circumstances, Cell Genesys will reduce its staff of 290 by approximately 75 percent by year-end with further reductions anticipated in the first half of 2009 as additional activities are phased out. As of September 30, 2008, the Company had approximately $150 million in cash and currently estimates that the year-end cash will be approximately $128 million. Personnel-related restructuring charges of approximately $12.8 million are expected to be incurred in the fourth quarter of 2008. The Company plans to provide updated financial guidance during its third quarter conference call in early November.

    "We are, needless to say, extremely disappointed with the outcome of the futility analysis for the VITAL-1 Phase 3 clinical trial, but remain committed to learning as much as we can about the potential role for immunotherapy in the treatment of cancer. On behalf of the Cell Genesys management team, I would like to express my deep gratitude to the courageous patients who participated in this study as well as our committed clinical trial investigators and their teams," stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. "At this time I would also like to extend my heartfelt thanks to the hardworking and dedicated employees of Cell Genesys to whom we must now sadly say goodbye. The significant changes in our business which we are implementing today are painful but necessary, and will enable us to consider the appropriate strategic alternatives for our company."

    In related news, Cell Genesys also announced the results of a preliminary analysis of the VITAL-2 Phase 3 clinical trial which, as noted above, was terminated on August 27, 2008. In contrast to the VITAL-1 study, the VITAL-2 study was conducted in patients with symptomatic metastatic hormone-refractory prostate cancer and compared the combination of GVAX immunotherapy plus Taxotere to Taxotere plus prednisone as a control. At the time this study was terminated, the IDMC reported an imbalance in deaths between the two treatment arms that was observed during a routine safety monitoring meeting of the committee. More specifically, of 114 deaths at the time of the IDMC review, 67 occurred in the GVAX immunotherapy plus Taxotere combination treatment arm and 47 in the Taxotere plus prednisone control arm. A total of 408 patients had been enrolled in the study up to that point in time. The Company has now conducted an initial analysis of the incomplete clinical trial data set that was reviewed by the IDMC in August. The analysis has revealed no apparent imbalance in patient baseline characteristics with respect to both demographic and disease prognostic factors. In addition, no significant toxicities in the GVAX immunotherapy plus Taxotere combination therapy arm were observed that could explain the imbalance in deaths and in fact, the vast majority of deaths in both treatment arms were reported as due to progression of prostate cancer. Of note, fewer treatment cycles with Taxotere were administered to patients in the GVAX immunotherapy plus Taxotere arm compared to the control arm, a difference which was statistically significant.

    About VITAL-1 and VITAL-2

    VITAL-1 was a Phase 3 clinical trial designed to compare GVAX cancer immunotherapy as a monotherapy to Taxotere chemotherapy plus prednisone in hormone-refractory prostate cancer patients with metastatic disease who were asymptomatic with respect to cancer-related pain. The primary endpoint of the trial was an improvement in survival. In 2007, the VITAL-1 trial completed enrollment with 626 patients. In January 2008, Cell Genesys announced that the IDMC had completed a pre-planned interim efficacy analysis for VITAL-1 and recommended that the study continue, providing no further information to the Company other than the recommendation to continue the trial. On August 27, 2008, the Company announced that it had requested the IDMC to conduct a previously unplanned futility analysis of VITAL-1. Based on the results of that analysis, the Company terminated the VITAL-1 trial, as announced today. VITAL-2 was a Phase 3 trial designed to compare GVAX immunotherapy in combination with Taxotere to Taxotere plus prednisone in hormone-refractory prostate cancer patients with metastatic disease who were symptomatic with respect to cancer-related pain. The primary endpoint of the trial was an improvement in survival. VITAL-2 was initiated in June 2005 and had enrolled 408 patients at 115 clinical trial sites located in North America and the European Union at the time of termination in late August. On August 27, 2008, the Company announced its decision to terminate VITAL-2 as recommended by its IDMC which, in a routine safety review meeting held that week to review both VITAL-1 and VITAL-2, observed an imbalance in deaths between the two treatment arms of the VITAL-2 study.

    About GVAX Immunotherapy for Prostate Cancer

    GVAX immunotherapy for prostate cancer is comprised of two prostate tumor cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine that plays a key role in stimulating the body's immune response, and then irradiated for safety. GVAX immunotherapy for prostate cancer is designed to be administered through intradermal injections on an outpatient basis.

    Conference Call and Webcast

    Members of the Cell Genesys management team will host a conference call today, October 16, 2008, at 8:30 a.m. ET to discuss this announcement. Investors may listen to the webcast of the conference call live on the investor section of the Cell Genesys website, www.cellgenesys.com. Alternatively, investors may listen to a replay of the call by dialing (800) 475-6701 from locations in the U.S. and (320) 365-3844 from outside the U.S. The call-in replay and webcast will be available for at least 72 hours following the call. Please refer to reservation number 965170.

    About Cell Genesys

    Cell Genesys (Nasdaq:CEGE) is focused on the development and commercialization of novel biological therapies for patients with cancer. The Company's lead product platform is GVAX(R) immunotherapy for cancer, which holds the potential to treat multiple types of cancer including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, California, and has manufacturing operations in Hayward, California. For additional information, please visit the Company's website at www.cellgenesys.com.

    Statements made herein about the company, other than statements of historical fact, including statements about estimated restructuring charges and cash position, and the company's progress, results, findings, analysis and timing of clinical trials and preclinical programs, the review of the GVAX program and exploratory analyses discussed above and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, regulatory requirements and the regulatory approval process for clinical trials, manufacture and commercialization of the company's products, competitive technologies and products, the need for and reliance on partnerships with third parties, and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's reports on Form 10-Q, 10-K, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.

    Source: Cell Genesys, Inc.
    Avatar
    GuHu1
    schrieb am 16.10.08 20:28:05
    Beitrag Nr. 78 (35.595.576)
    Antwort auf Beitrag Nr.: 35.594.618 von asics01 am 16.10.08 18:50:54
    das war es wohl, ja für cege schon!
    Avatar
    Larry_1
    schrieb am 30.10.08 16:47:20
    Beitrag Nr. 79 (35.766.036)
    seit 3 Tagen Rebound (leider ohne mich):mad:
    Avatar
    OnlineBrooker
    schrieb am 04.11.08 22:22:49
    Beitrag Nr. 80 (35.830.655)
    Das ganze sieht mir sehr nach einem Anlauf zu alten höhen aus :-)

    Wenn jetzt mal positive News kommen, dann wird das hier bestimmt ordentlich knallen!
    Avatar
    Moneymaker123
    schrieb am 06.11.08 15:24:36
    Beitrag Nr. 81 (35.855.009)
    Oft erlebt man das gerade die Werte steigen bei denen
    das Board sehr ruhig ist.

    CEGE ist wahrscheinlich so ein Wert.

    Habe gestern mal zu 0,325 welche gekauft.

    Scheint weiter aufwärts zu gehen.:lick::lick:
    Glaube in Germany kriegt es kaum einer mit!:yawn::yawn::laugh:

    Heute scheint noch was zu kommen TH sehe ich bei über 0,6 $
    Avatar
    Moneymaker123
    schrieb am 06.11.08 23:19:20
    Beitrag Nr. 82 (35.861.581)
    Na da war ich wohl zu optimistisch.
    Die Quartalszahlen sind aber ok und haben sich zu VJ stark
    verbessert.

    12,5 MIO Short machen hier alles zunichte und es wird wohl wieder
    abwärts gehen!:mad::mad:
    Avatar
    Moneymaker123
    schrieb am 07.11.08 07:53:46
    Beitrag Nr. 83 (35.864.854)
    Das Ask sieht ja heute super aus- da steht 10.-$:lick::lick:
    Na wenn es wenigstens grün wird bin ich erstmal zufrieden.

    Man strebt einen 80%tigen Personalabbau bis Jahresende an.
    60% sind schon realisiert.(=116 MA heuer)(58MA am 31.12.2008)
    das senkt die Kosten dramatisch
    In 2009 will man weiteres Personal abbauen.

    118-120 MIO Cash wird man bis Jahresende (150 MIO jetzt).

    Je Share steht ein Eigenkapital von 1,78$:eek: und am Jahresende von 1,42$ gegenüber!:eek:

    Zudem strebt man einen Merger an und könnte sich vorstellen
    es mit Takeda Pharmaceutical Company Limited
    einen bisherigen Auftraggeber o. anderen zu machen .

    Schade das die Erprobungsphasen für das Prostatamittel gecancelt
    wurden denn damit hätte man einen Durchbruch geschafft.

    Aber es stehen noch andere Dinge an wie z.B Alzheimer
    Präparate wo gerade 4,5 MIO zu weiteren Forschungszwecken in die
    Kasse gespült wurden.

    GLTA;)
    Avatar
    Moneymaker123
    schrieb am 07.11.08 09:27:09
    Beitrag Nr. 84 (35.865.944)
    Ruhe vor dem Sturm?

    Selbst im Ihub ist es seltsam still.

    Ein Funke und die offenen Shorts lassen den Kurs
    wohl ansteigen- ansonsten eher seitwärts.

    GLTA
    Avatar
    Chalif
    schrieb am 08.11.08 12:36:28
    Beitrag Nr. 85 (35.882.556)
    Hier könnte es so enden wie bei Atherogenics (Chapter 11).Leute,ich war selber drin in atherogenics,ihr glaubt garnicht wie schnell hier die Lichter ausgehen.Cell Genesys hat einen ähnlich hohen verschuldungsgrad wie ihn atherogenics hatte ....

    MFG
    Chali :look:
    Avatar
    OnlineBrooker
    schrieb am 09.11.08 14:11:49
    Beitrag Nr. 86 (35.891.735)
    Antwort auf Beitrag Nr.: 35.882.556 von Chalif am 08.11.08 12:36:28Ich denke eher, dass es hier zu einem ordentlichen Rebound kommen wird (nur meine Meinung). Wie´s aussieht sind die Quartalszahlen raus, der Kurs hat einen kurzen Einsturz hingelegt und hat dennoch höher geschlossen als wie gedacht,... I stay long :cool:
    Avatar
    Chalif
    schrieb am 09.11.08 15:50:52
    Beitrag Nr. 87 (35.892.417)
    Das mit dem ordentlichen rebound glaubst du doch selber nicht :rolleyes: !Alle Drugs von Cell Genesys sind gescheitert,Leute sind in den Phase 2 Tests gestorben,hohe Verschuldung etc.

    Hier ist nichts meht zu holen,nichts wie raus .. :eek::eek::eek: !!
    Avatar
    OnlineBrooker
    schrieb am 09.11.08 16:16:38
    Beitrag Nr. 88 (35.892.591)
    Antwort auf Beitrag Nr.: 35.892.417 von Chalif am 09.11.08 15:50:52o.k. dann erklär mir doch mal den Hype der letzten Tage in den U.S.A. ;-) Wie erklärst du dir diese täglichen Gewinne??? Ich denke, hier ist mehr zu holen als wie manche glauben möchten...
    Avatar
    Moneymaker123
    schrieb am 10.11.08 10:22:08
    Beitrag Nr. 89 (35.899.469)
    Antwort auf Beitrag Nr.: 35.892.417 von Chalif am 09.11.08 15:50:52Hier sind noch etliche Short .
    Ich stelle fest das es wahrscheinlich ist, das Du dazu gehörst
    oder zum bashen abgestellt wurdest.

    Du erwähnst nämlich gar nicht das die Prostatastudie/Testreihe deswegen abgebrochen wurde weil es zu den bisherigen Mittel keine sigifikant positiven Ausschläge gab.
    Aber auch da verstarben die Patienten!

    Am Mittwoch gibt es eine Konferenz und CEGE sucht einen
    Mergerkanditaten .
    Vielleicht hat sich im Vorfeld schon etwas abgezeichnet
    wie sonst ist der EOD run am Freitag zu erklären ?

    Das Quartalsergebnis ist aufgrund der Einflüsse des Geldflusses für die Testreihe des Prostatakrebsmittels o.K was aber nun entfällt.
    Man hat sofort 60% MA entlassen und ist am 31.12.2008 auf 80 %.

    Den Rest des Unternehmens will man mit einem anderen Konzern verschmelzen.Für die Alzheimer Studie gab es gerade 4,5 MIO
    an Cash welches die Glaubwürdigkeit der AG nicht gerade
    verschlechtert!;);)

    Es gibt noch Assets und am Jahresende stehen ca.
    120 MIO $ auf der Haben Seite!

    Ein Kurs von 1,4$ ist gerechtfertigt.
    Mit Shorties die nun Angst haben geht es evtl. auch höher!;)
    Avatar
    OnlineBrooker
    schrieb am 11.11.08 16:28:21
    Beitrag Nr. 90 (35.912.476)
    Hält sich doch gut unser Baby. Jetzt demnächst mal eine positive Nachricht und der Aufstieg kann beginnen :cool:
    Avatar
    GuHu1
    schrieb am 05.12.08 17:56:00
    Beitrag Nr. 91 (36.156.367)
    Cell Genesys and Takeda terminate collaboration agreement
    Thursday December 04, 2008 09:38:41 EST
    Dec 04, 2008 (Datamonitor via COMTEX News Network)


    Cell Genesys, a biotechnology company, and Takeda Pharmaceutical Company, together with its wholly owned subsidiary Millennium Pharmaceuticals, have mutually agreed to suspend the further development of Gvax immunotherapy for prostate cancer.

    Takeda has also ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.

    Under the terms of the agreement, Takeda will return all commercial rights to Gvax immunotherapy for prostate cancer to Cell Genesys and make certain wind-down payments to Cell Genesys in connection with the phasing out of the remaining clinical development activities.
    Avatar
    Larry_1
    schrieb am 27.03.09 10:02:02
    Beitrag Nr. 92 (36.861.761)
    ha, plötzlich bin ich wieder im Plus :kiss:
    Frage ist, wie geht es heute weiter :confused:
    Avatar
    Larry_1
    schrieb am 27.03.09 10:05:53
    Beitrag Nr. 93 (36.861.817)
    gibt es wieder neues zu GVAX ?
    oder Übernahme ?
    Avatar
    Larry_1
    schrieb am 14.04.09 15:16:05
    Beitrag Nr. 94 (36.965.132)
    hmm, knallt wieder mal nach oben :eek::eek::eek:
    Avatar
    Larry_1
    schrieb am 14.04.09 15:17:28
    Beitrag Nr. 95 (36.965.141)
    :eek:
    Pre-Market After Hours $0.63Change: +0.28 +80.00%Volume: 1,456,978
    Avatar
    _poseidon
    schrieb am 15.04.09 10:19:35
    Beitrag Nr. 96 (36.969.927)
    moin

    After Hours
    Last: $ .47

    habe mich positioniert :)
    Avatar
    _poseidon
    schrieb am 15.04.09 10:22:16
    Beitrag Nr. 97 (36.969.951)
    hier noch eine empfehlung für heute:

    http://stockreads.com/

    also wenn das keine guten voraussetzungen sind ....
    Avatar
    _poseidon
    schrieb am 16.04.09 07:51:04
    Beitrag Nr. 98 (36.976.621)
    moin

    After Hours
    Last: $ .45 After Hours
    High: $ .50
    After Hours
    Volume: 40,687 After Hours
    Low: $ .44

    hier noch ein kleiner auszug aus'm yahoo forum

    3 NEW REPORTS CEGE NEWS TODAY 15-Apr-09 09:00 pm

    $84 IN REPORTS FOR CEGE CAME OUT TONIGHT. CEGE HAS NEWS FOR THE MOVERS. REPORTS AREN'T MADE FOR COMPANIES WHICH HAVE NOTHING.
    Avatar
    Larry_1
    schrieb am 20.04.09 18:49:16
    Beitrag Nr. 99 (37.004.275)
    läuft seit Tagen mit starkem Volumen nach oben :cool:

    hat jemand ne Ahnung, weshalb?
    Avatar
    asics01
    schrieb am 20.04.09 19:20:17
    Beitrag Nr. 100 (37.004.465)
    Antwort auf Beitrag Nr.: 37.004.275 von Larry_1 am 20.04.09 18:49:16läuft nur mit dendreon mit
    Avatar
    Larry_1
    schrieb am 20.04.09 21:39:38
    Beitrag Nr. 101 (37.005.438)
    und mit GPC biotec, Wilex,und und und

    egal,bin auf jeden Fall mal wieder eingestiegen
    Avatar
    Marchella
    schrieb am 20.04.09 22:27:33
    Beitrag Nr. 102 (37.005.832)
    kommt mal auf die Watch ;)
    Avatar
    BrauchGeld
    schrieb am 20.04.09 22:37:19
    Beitrag Nr. 103 (37.005.901)
    Antwort auf Beitrag Nr.: 37.005.832 von Marchella am 20.04.09 22:27:33Würde lieber die Finger von lassen ...Fakt ist Gvax wurde eingestellt finito nada und die zusammenarbeit mit Takeda wurde auch beendet hier ist nix mehr Zukunft außer man will zocken ..

    Harry A. can't seem to let Cell Genesys (CEGE Quote) die a quiet, peaceful death.

    "If in your opinion Cell Genesys is done, then explain why Leroy Kopp [Kopp Investment Advisors] increased his position by buying 600,000 shares in February? Do you think they are doing this to throw money away? You seem to know so much, just like Cramer does. To me, you and him are alike, you both pump and bash for your hedge fund buddies."

    I don't know why Kopp is buying more Cell Genesys, if indeed the firm is buying. (I'll take Harry at his word.) But here is what I do know about Cell Genesys: I first raised serious questions about the company's cancer vaccine technology in February 2004 when the stock traded in the teens. I continued to warn readers off the stock throughout 2007 before the company's prostate cancer vaccine blew up spectacularly. You can read the highlights here and here and here.

    Today, Cell Genesys is an empty shell of a company with a stock that trades for around 20 cents. Drug development is on hold, the employee count is down to 21, and the company is looking for a buyer.

    So, I wish Kopp and Harry good luck with Cell Genesys. I think my bearish call performed exceedingly well.
    Avatar
    VaJo
    schrieb am 21.04.09 07:35:14
    Beitrag Nr. 104 (37.006.523)
    Antwort auf Beitrag Nr.: 37.005.901 von BrauchGeld am 20.04.09 22:37:19Guten Morgen,

    kann es sein das CEGE beim Anlegen der GVax Studie damals einen Fehler gemacht hat?

    Schließlich traten die Todesfälle in Kombination mit Taxotere auf, also bei Patienten die schon stark vorbehandelt und austherapiert waren.

    Der vermutete Erfolg bei Provenge könnte GVax eine neue Dimension geben, z.b. beim ausarbeiten einer neuen Studie. Immerhin hat Cell Genesys keine Schulden und rund 60 Mio in Cash.

    Ich weis nicht ob der Anstieg gestern vielleicht doch einige zu der Annahme veranlaßt hat.
    Avatar
    VaJo
    schrieb am 21.04.09 07:39:00
    Beitrag Nr. 105 (37.006.531)
    Dieser Satz hier aus dem Artikel bzgl. der Studienaufgabe läßt mich aufhorchen.

    Earlier-stage trials have shown that patients taking GVAX lived for about 35 months _ or longer, if they had an immune response to the drug _ compared with about 25.2 months for Provenge and, Pantginis said, 18 or 19 months for the standard treatment, Sanofi-Aventis' Taxotere.

    Wenn CEGE deutlich über 1 Dollar steigt wäre das für mich ein Zeichen das vielleicht darüber nachgedacht wird.
    Avatar
    VaJo
    schrieb am 21.04.09 07:59:28
    Beitrag Nr. 106 (37.006.594)
    Wenn man sich den Chart anschaut könnte man das auch vermuten ;)

    Avatar
    Larry_1
    schrieb am 21.04.09 09:02:11
    Beitrag Nr. 107 (37.006.914)
    Anstieg die letzten Tage mit hohem Volumen und teilweise beträchtlichen Orders ist für mich immer ein gutes Indiz
    Der Anstieg ist also fundamental begründet und nicht nur als Zock zu sehen

    good trade
    :)
    Avatar
    VaJo
    schrieb am 21.04.09 12:18:59
    Beitrag Nr. 108 (37.008.516)
    Nach der Beendigung der Zusammenarbeit mit Takeda Ch. wird das Interesse durch die DNDN Meldung an einer Vaccine Therapie wieder steigen. Vielleicht kriegen wir hier bald die Meldung das ein großer Pharma Interesse an der Fortführung des Programms hat.
    Warum sollte sonst CEGE so stark und unter so einem hohen Volumen steigen, wenn die immer noch Däumchen drehen?
    Avatar
    _poseidon
    schrieb am 21.04.09 12:34:52
    Beitrag Nr. 109 (37.008.650)
    Antwort auf Beitrag Nr.: 37.006.914 von Larry_1 am 21.04.09 09:02:11Tach

    da stimme ich dir 100% zu
    Avatar
    BrauchGeld
    schrieb am 21.04.09 13:38:36
    Beitrag Nr. 110 (37.009.127)
    Antwort auf Beitrag Nr.: 37.006.914 von Larry_1 am 21.04.09 09:02:11Anstieg die letzten Tage mit hohem Volumen und teilweise beträchtlichen Orders ist für mich immer ein gutes Indiz
    Der Anstieg ist also fundamental begründet und nicht nur als Zock zu sehen


    Ich denke es hat einfach damit zu tun das CEGE weit unter Cash notiert sonst sehe ich nichts was den Anstieg begründet .

    Balance Sheet...
    Total Cash (mrq): 83.21 M$
    Total Cash Per Share (mrq): 0.959 << CEGE ist aktuell bei 0,68 $
    Avatar
    VaJo
    schrieb am 21.04.09 14:33:43
    Beitrag Nr. 111 (37.009.577)
    :laugh:

    BINGO ich habs doch gesagt ....


    Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin

    * Tuesday April 21, 2009, 1:30 am EDT

    *
    Buzz up!
    * Print

    Related:

    * Cell Therapeutics, Inc.

    Identifies potential clinical trial strategies for personalized approach to cancer treatment
    Related Quotes
    Symbol Price Change
    CTIC 0.31 0.00
    Chart for Cell Therapeutics, Inc.
    {"s" : "ctic","k" : "c10,l10,p20,t10","o" : "","j" : ""}

    SEATTLE, April 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC), presented data from a preclinical study, which utilized RNA interference (RNAi) and bioinformatics to identify genetic markers - "contexts of vulnerability" - that enhance the anti-tumor response to the experimental drug candidate brostallicin, at the 2009 American Association for Cancer Research (AACR) annual meeting in Denver, Colorado. "Contexts of vulnerability" refers to the genetic configuration in a patient's tumor that makes it susceptible to a specific drug thus providing the genetic rationale for targeted therapy. The study's objective was to identify molecular determinants of brostallicin's anti-tumor response that could guide clinical development and drug combination studies by incorporating an integrated pharmacogenomics approach. The study was conducted by SM in collaboration with the Translational Genomics Research Institute's Pharmaceutical Genomics Division in Scottsdale, Arizona.

    "This study has identified certain patient groups which might be more likely to benefit from therapy with brostallicin and have been invaluable in assisting us in identifying promising clinical development strategies for future development of this novel drug candidate," said Jack Singer, M.D., Chief Medical Officer of CTI. "Ultimately, we believe this approach should shorten the clinical development time and increase the success rate by bringing us closer to being able to offer the right drug to the appropriate patient."

    Brostallicin is a small-molecule chemotherapeutic agent with a unique mechanism of action -- it binds to the minor grooves located in the DNA double helix. To identify genes associated with cellular response to brostallicin, a high-throughput RNA interference screen was performed in selected ovarian cancer cell lines. RNA interference is a cellular process that results in the targeted knockdown of specific genes. The current screen assayed the effect of over 7,000 individual gene knockdowns, representing the "druggable" genome, on brostallicin response.

    The identified genes, representing unique contexts of vulnerability to brostallicin, converged on cellular concepts relating to DNA repair and chromosome modification. These findings were further extended and confirmed in breast cancer cell lines, wherein the knockdown of specific genes involved in these concepts, mentioned above, resulted in an increased response to brostallicin.

    To substantiate the brostallicin response observed in the RNAi studies, drugs that target selected genetic targets were tested for synergistic activity in combination with brostallicin. The outcome of this validation work has identified important contexts and rational drug combinations that will be critical for the clinical development of brostallicin.

    To review the poster and see more detailed information about the study, please go to http://www.celltherapeutics.com/investor_updates.

    About Brostallicin

    Brostallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

    About Systems Medicine (SM)

    In July 2007, CTI acquired Systems Medicine, a privately held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs--the "context of vulnerability."

    About Cell Therapeutics, Inc.

    Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

    Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/news_subscription_service

    This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular, including, without limitation, the potential failure of the preclinical results to predict results in clinical trials, the potential failure of the clinical results to predict the safe and effective treatment of cancer, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors particularly ovarian or colon cancers, determinations by regulatory, patent, and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing, and selling brostallicin, and the risk factors listed or described from time to time in the CTI's filings with the Securities and Exchange Commission including, without limitation, the CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com
    Avatar
    VaJo
    schrieb am 21.04.09 14:50:27
    Beitrag Nr. 112 (37.009.691)
    Ich vermute heute mal Schlusskurs 1,50 Dollar ;)
    Avatar
    Larry_1
    schrieb am 21.04.09 15:27:59
    Beitrag Nr. 113 (37.009.944)
    Das ist ja der Hammer
    die Cege bringt mir jetzt seit ca. 2 Jahren immer wieder Extreme Gewinne.
    Allerdings trade ich diese Aktie nur, d.h. heute werde ich dann vermutlich wieder rausgehen.

    Bin in der Arbeit...
    Kannst du paar deutsche Interpretationen geben, was jetzt hier Sache ist??
    Avatar
    VaJo
    schrieb am 21.04.09 15:44:08
    Beitrag Nr. 114 (37.010.086)
    Ich bin auch noch auf der Arbeit. Heute abend muss ich mich mal näher einlesen. Aber Insider haben da im Vorfeld gekauft. Anders kann man die Kursentwicklung und die heutige Meldung nicht werten.

    Bei CEGE gehts weiter und mit reichlich Cash und ohne Schulden... :D
    Avatar
    VaJo
    schrieb am 21.04.09 15:44:48
    Beitrag Nr. 115 (37.010.094)
    Bin heute eingestiegen.
    Avatar
    Larry_1
    schrieb am 21.04.09 15:52:54
    Beitrag Nr. 116 (37.010.184)
    Danke Dir :)
    Avatar
    Larry_1
    schrieb am 21.04.09 16:03:44
    Beitrag Nr. 117 (37.010.301)
    momentan geht es down:confused:
    ich mach jetzt Feierabend
    mal schaun, wie es heute abend ausschaut
    Avatar
    strike321
    schrieb am 21.04.09 16:56:10
    Beitrag Nr. 118 (37.010.727)
    Antwort auf Beitrag Nr.: 37.009.577 von VaJo am 21.04.09 14:33:43Du weißt schon, dass es in dem Artikel um "Cell Therapeutics" und nicht um "Cell Genesys" geht?

    Gruß
    strike321
    Avatar
    BrauchGeld
    schrieb am 21.04.09 17:09:00
    Beitrag Nr. 119 (37.010.855)
    Antwort auf Beitrag Nr.: 37.010.727 von strike321 am 21.04.09 16:56:10Wenigstens einer der die Augen offen hat :laugh::laugh::laugh::laugh:
    Avatar
    VaJo
    schrieb am 21.04.09 17:23:31
    Beitrag Nr. 120 (37.011.006)
    Oh sorry,
    das ist eine CTIC Meldung :laugh:
    kommt davon wenn man schnell schnell in der Pause liest...

    :kiss:
    Avatar
    asics01
    schrieb am 21.04.09 17:52:43
    Beitrag Nr. 121 (37.011.330)
    Antwort auf Beitrag Nr.: 37.010.094 von VaJo am 21.04.09 15:44:48Bin heute eingestiegen

    wegen des CTI artikels,bist du bei CEGE rein:confused::confused:
    Avatar
    VaJo
    schrieb am 21.04.09 18:09:06
    Beitrag Nr. 122 (37.011.462)
    Ich bin heute morgen in CEGE rein. Und heute Mittag hab ich schnell die Finanznachrichten durchgesehen und bin über den Artikel gestolpert. Jetzt bin ich nach Hause gekommen und habs selbst gemerkt das es nicht CEGE heißt sonder CTIC.
    Die Hähme schenk ich euch :D


    Von CEGE bin ich trotzdem angetan und hoffe das in nächster Zeit eine positive Neuigkeit kommt. Schließlich hocken die jetzt auf ihrem Geld und drehen Däumchen.

    Der Artikel hat 2 Stunden nach meinem Einstieg aber auch genau gepasst :laugh: wäre zu schön gewesen.

    Sorry wenn dadurch jemand veranlaßt wurde einzusteigen. Das war nicht meine Absicht.
    Avatar
    VaJo
    schrieb am 21.04.09 18:30:31
    Beitrag Nr. 123 (37.011.638)
    Schaut mal wer bei CEGE verkauft und wer kauft.

    http://finance.yahoo.com/news/JPMorgan-Insider-Sells-12M-tsm…

    Instis verkaufen und das Management von CEGE kauft Aktien.
    Verwunderlich, nomalerweise ist das umgedreht.
    ;)
    Avatar
    Larry_1
    schrieb am 21.04.09 18:43:02
    Beitrag Nr. 124 (37.011.740)
    na ja, kann in der Hektik passieren

    Ich bleibe vorerst mal weiterhin bei Cege investiert.
    Hoffe aber natürlich, das es demnächst mit dem Kurs weiter up geht
    Heute die Gewinnmitnahmen sind für mich noch ok.
    Viel Glück
    :cool:
    Avatar
    asics01
    schrieb am 21.04.09 18:55:15
    Beitrag Nr. 125 (37.011.862)
    Antwort auf Beitrag Nr.: 37.011.462 von VaJo am 21.04.09 18:09:06antigenics (AGEN) schwimmt auch auf der welle mit,ist auch interesannt
    Avatar
    VaJo
    schrieb am 21.04.09 19:43:05
    Beitrag Nr. 126 (37.012.301)
    Die Gewinnmitnahme stört mich auch nicht.
    GVax wird neu aufgelegt, da bin ich mir sicher. Schon allein wegen der vielen Wunderheilungen, z.b. im Jahr 2000 als ein Mann mit fortgeschrittenem Lungenkrebs mit GVax vollständig geheilt wurde. Googelt mal nach dem Artikel. Kam im Fernsehen.
    Avatar
    VaJo
    schrieb am 21.04.09 19:47:33
    Beitrag Nr. 127 (37.012.338)
    Sorry wenn sich das lächerlich anhört. Für mich hat dieses Vaccine Thema immer noch einen Touch Wunderheilung. ;)
    Aber der Trend ist dein Freund...
    Avatar
    VaJo
    schrieb am 21.04.09 19:53:04
    Beitrag Nr. 128 (37.012.378)
    GVAX immunotherapy for prostate cancer in combination with Taxotere to Taxotere plus prednisone

    Diese Therapie muste ja die Patienten umbringen, kein Wunder das sie wie die Fliegen gestorben sind. Austherapiert, dann die doppelte Chemiekeule und obendrauf noch umgepolte Antikörper. So wie es aussieht wollte man ein Hammerergebnis erzwingen.

    Sanfte Medzin wie es diese Art verspricht sieht anders aus. Vielleicht bewirkt gerade die Immuntherapie etwas im Bewustsein der Patienten die dann darauf reagieren?
    Avatar
    VaJo
    schrieb am 21.04.09 19:58:10
    Beitrag Nr. 129 (37.012.412)
    In Cuba ist übrigens ein Vaccine gegen Lungenkrebs zugelassen. CimaVax heißt das Wunderverfahren.

    Googelt mal danach, lauter Heilungen...
    Avatar
    VaJo
    schrieb am 21.04.09 20:00:07
    Beitrag Nr. 130 (37.012.424)
    1:09 p.m. EST, Thu February 19, 2009

    By Shasta Darlington
    CNN

    HAVANA, Cuba (CNN) -- Terminal lung cancer patients are living longer thanks to the world's first registered lung cancer vaccine, a leading Cuban scientist says.
    Dr. Gisela Gonzalez

    Cuban scientist Dr. Gisela Gonzalez says she and her team have created a lung cancer vaccine that extends patient's lives.

    Dr. Gisela Gonzalez has spent years researching the vaccine which the Cuban government approved for the use of the general public last year.

    Gonzalez and her team have worked on developing the CimaVax EGF vaccine at the Cuban Center of Molecular Immunology since the early 1990s.

    She says all those years of hard work have finally paid off as trials show that Cubans with lung cancer are living a little longer after having the vaccine.

    "One of my early patients was a 32-year-old man when he started taking the vaccine. I had a son that age," the scientist told CNN.

    "Now he's 35. He's living and working. He visited us the other day and said he's thinking about having kids."

    Gonzalez says that more than 700 patients have received the vaccine over the years, many of them in seven clinical trials in Cuba, Canada and the UK.

    More than 400 advanced lung cancer patients received the Vaccine CimaVax EGF in the trials, according to the Latin American News Agency.
    Vital Signs
    Each month CNN's Dr. Sanjay Gupta brings viewers health stories from around the world.
    See more from the show »

    The trials showed that the drug extended the life of terminal patients by an average of four months, and in some cases several years, compared with those patients who only received traditional therapies. Younger patients tended to fare better.

    "It has the potential to be very important," according to Dr. Howard Burris, director of drug development at the Sarah Cannon Research Institute in Nashville, Tennessee.

    He said the results were comparable to those being produced by two other lung cancer vaccines, GVAX and BLP 25, being developed in the United States.

    "Larger trials will show there are subsets that it's very good for and for others it's not relevant," he said.

    CimaVax EGF does not prevent or cure lung cancer. It is a therapeutic vaccine which stimulates the patient's body to make an antibody against the epidermal growth factor (EGF), which is a key driver causing lung cancer cells to grow.

    It is used in conjunction with chemotherapy and radiation therapy which reduce the size of the initial tumor.
    Don't Miss

    "With this kind of product, maybe cancer, advanced cancer, can be treated like any other chronic disease like diabetes," Dr. Gonzalez said during a recent tour of her modern laboratory in Havana.

    Medical services, even the most costly, are provided free of charge in communist Cuba. CimaVax EGF is now part of routine treatment for advanced lung cancer patients.

    Experts say that success is due in large part to a focus on preventative medicine and a very local approach to health that includes thousands of neighborhood physicians.

    Cuba has also developed a formidable biotechnology industry championed by Fidel Castro as early as the 1980s. Doctors here developed vaccines for Meningitis B and Hepatitis B which are now being used in a number of countries. Medical tourism is also on the rise, attracting paying patients from abroad.

    Dr. Gonzalez said CimaVax EGF has sparked a lot of interest internationally. She has advised foreign patients interested in the vaccine to seek approval from their national regulatory agencies to use it in their home country. She said two patients, one from Australia and one from Argentina, have already succeeded in doing so.

    In December, a lung cancer patient from Australia Liz Simon, wrote on a lung cancer forum Lungevity "Well it's actually arrived. After negotiations over six months, the CimaVax vaccine has actually arrived in Brisbane."

    Simon wrote that she was undergoing radiation treatment and would have to wait four weeks after that before starting the vaccine.

    "The vaccine's bona fides will be checked out before I start. And I will be using it under scientific conditions so that we can judge its efficacy. So let's see - I am happy to...become the resident guinea pig," she added.

    The Cuban team is now starting a clinical trial in Malaysia and hopes to begin others in China, India and Peru.

    Dr. Burris said an article last year by the Cuban doctors in the Journal of Clinical Oncology made a big splash in the scientific community, injecting new enthusiasm into U.S. research on the topic.

    "It's hard to get an antibody response once you've had chemotherapy," he said. "So if you have a vaccine and it works even half the time, that's pretty fabulous."
    Avatar
    VaJo
    schrieb am 21.04.09 20:05:43
    Beitrag Nr. 131 (37.012.468)
    Einfach gesprochen, das ist ein riesen Hype der da abgeht. Und das ganze wird noch schlimmer werden. In den kommenden Jahren werden ständig neue Firmen auftauchen die sich mit dem Theam beschäftigen. Würde mich nicht wundern wenn jetzt plötzlich eine GPC Biotech in die Vaccine Forschung einsteigt.
    Bis zur FDA Entscheidung über Provenge im Oktober werden täglich neue Wunder vermeldet werden.
    Vielleicht sehen wir auch den Einbruch der Kurse bei klassischen Chemo Herstellern.
    Mal schauen ob dann die Blase im Herbst platzt...
    Avatar
    VaJo
    schrieb am 22.04.09 06:42:49
    Beitrag Nr. 132 (37.014.126)
    Board Director Kopp hat in 2 Tagen 400.000 Stck gekauft. Entweder kommt eine Neuauflage von GVax oder CEGE wird verkauft.

    Was meint ihr?
    Avatar
    Larry_1
    schrieb am 22.04.09 07:33:44
    Beitrag Nr. 133 (37.014.222)
    Guten morgen

    Bist Du schon wieder aktiv?
    Ist doch positiv zu werten wenn Kopp aufstockt.
    Warum auch immer, ist mir letztendlich egal Hauptsache der Kurs bricht nicht mehr runter
    Avatar
    VaJo
    schrieb am 22.04.09 12:42:17
    Beitrag Nr. 134 (37.016.528)
    Wichtig wäre das Cell G. mal in nächster Zeit ihre neuen Ziele definiert. Immerhin ist das die Biotechfirma die die meisten Patente hält wenn man dem Internet glauben darf.

    Wie gesagt ich rechne damit das GVax neu aufgelegt wird. Diesmal ohne Chemo und Austherapierte Patienten.
    Avatar
    Larry_1
    schrieb am 22.04.09 21:32:23
    Beitrag Nr. 135 (37.021.455)
    Kurs hat sich wieder schön im Plus stabilisiert ;)
    Avatar
    VaJo
    schrieb am 23.04.09 09:54:21
    Beitrag Nr. 136 (37.023.711)
    A discussion between “rufustoehee”, a poster on the DNDN Investor Village Board and Hy Levitsky, MD, of John Hopkins, a leading medical oncologist and a co-inventor with Dr. Glenn Dranoff, Drew Pardoll and others of GVAX.
    Rufus: “Well, why do you think the Dendreon approach was successful versus the GVAX ‘ s problem?
    Dr. Levitsky: Well, I think that will be a subject of considerable debate that will be greatly aided by having the data out there for people to look at in detail. At this point of ignorance, I am willing to bet you that a major parameter was that GVAX went up against Taxotere and Provenge went up against the placebo”
    It’s time for the FDA to listen to some of America’s top research oncologists and approve both GVAX and Provenge in HRPC for patients with minimum Halabi Predicted Survival of 18 months or greater.


    Genau das was ich seit Tagen sage.

    Schaut euch die Daten zu GVax an. GVax hatte in den vorangegangen Studien immer einen höheren Überlebensvorteil als Provenge.

    Der Fehler den Cell Genesys machte war Gvax in Verbindung mit Taxotere und Predn. zu prüfen. Dadurch kam es zu den hohen Todesfällen. Hätten sie die Studie wie Dendreon vs Placebo durchgeführt wäre auch hier das Studienendziel aber mit 100% Wahrscheinlichkeit sehr viel besseren Ergebnis ausgefallen.

    Die Folge wird sein.

    Cell Genesys legt eine neue Studie auf (Geld haben sie genug).
    Die wird lauten.

    GVax vs Placebo

    12 Monate später werden wir alle überrascht über das Ergebnis sein
    Avatar
    Larry_1
    schrieb am 23.04.09 11:50:19
    Beitrag Nr. 137 (37.024.887)
    VaJo

    danke für Deine guten Beiträge :)
    Was hältst Du eigentlich von der WILEX Aktie?
    Avatar
    VaJo
    schrieb am 23.04.09 12:00:27
    Beitrag Nr. 138 (37.025.015)
    Antwort auf Beitrag Nr.: 37.024.887 von Larry_1 am 23.04.09 11:50:19Dazu weis ich gar nichts. Sorry.

    Auch GPC habe ich komplett nach der Satraplatin Verarsche gestrichen. Der Sammelklage habe ich mich angeschlossen weil das was da abgelaufen ist in meinen Augen schon kriminell war. Aber das kann jeder sehen wie er will.
    Avatar
    Larry_1
    schrieb am 23.04.09 12:20:46
    Beitrag Nr. 139 (37.025.244)
    Antwort auf Beitrag Nr.: 37.025.015 von VaJo am 23.04.09 12:00:27
    Aber das kann jeder sehen wie er will.

    so ist halt das Leben :D
    Avatar
    VaJo
    schrieb am 23.04.09 14:16:29
    Beitrag Nr. 140 (37.026.296)
    Man im Dendreon Forum wird schon begonnen Provenge als alleiniges Heilmittel zu stilisieren und viele glauben das.
    Dabei war/ist Provenge nur zweite Wahl.

    GVax Phase 2: GVAX after surgical resection of their tumor and adjuvant radiation and chemotherapy. The median overall survival for these patients was previously reported to be 26.8 months

    Ein zweite Phase III Studie wird aufgelegt werden, da bin ich mir ganz sicher. Die Frage ist nur wie sie designt ist.

    Ich glaube nicht das DNDN mit Provenge vs Placebo ein Approval erhält.
    Avatar
    Larry_1
    schrieb am 23.04.09 15:39:20
    Beitrag Nr. 141 (37.027.020)
    Antwort auf Beitrag Nr.: 37.026.296 von VaJo am 23.04.09 14:16:29Kann ich leider nichts dazu sagen/schreiben, bin zu weit vom Thema weg.

    aber CEGE startet gerade wieder schön positiv ;)
    Avatar
    VaJo
    schrieb am 23.04.09 17:57:31
    Beitrag Nr. 142 (37.028.520)
    Wenn Cell Genesys die Meldung über eine neue Studie bzgl. GVax bringen würde, stünde der Kurs binnen kürzester Zeit bei 10 Dollar.

    Irgendwas muss kommen. Ich kann mir nicht vorstellen das die mit ihren 70 Mio Cash da sitzen und zuschauen wie andere gefeiert werden, wohl wissend was in ihrer Entwicklung steckt.

    Seit Januar sammelt Cell Genesys Geld ein, durch den Verkauf von Anlagen und Büros. Warum?
    Die hätten mit ihrem Bargeld auch bequem weiter herumwursteln können.

    Meiner Meinung nach dient die Aktion einzig und allein dem Zweck den Grundstock für eine Studie ohne Partner zu bilden und auf Grundlage der alten Daten eine neue Studie zu starten.
    Avatar
    Magnetfeldfredy
    schrieb am 23.04.09 17:59:04
    Beitrag Nr. 143 (37.028.535)
    Antwort auf Beitrag Nr.: 37.026.296 von VaJo am 23.04.09 14:16:29Hoffentlich wirst Du so alt, daß Du es jemals erleben wirst, daß Cell Genesys so hoch steht wie Dendreon!:laugh:
    Avatar
    VaJo
    schrieb am 23.04.09 18:02:29
    Beitrag Nr. 144 (37.028.580)
    Antwort auf Beitrag Nr.: 37.028.535 von Magnetfeldfredy am 23.04.09 17:59:04Hoffentlich wirst Du so alt, daß Du es jemals erleben wirst, daß Cell Genesys so hoch steht wie Dendreon!

    Da muss ich vielleicht gar nicht so lange warten und Dendreon kommt Cell Genesys auf dem Weg nach oben entgegen. Kursziel 1 Dollar!

    Nämlich dann wenn die FDA im Oktober euren Standard of Care in der Luft zereißt.

    :D
    Avatar
    VaJo
    schrieb am 23.04.09 18:08:49
    Beitrag Nr. 145 (37.028.655)
    Vergessen wir nicht "Provenge Works" wurde 2007 auch schon verkündet und trieb die Aktie bis in die heutigen Regionen.

    2 Jahre später heißt es wieder "Provenge Works" diesmal mit einer Spezielstudie.

    Provenge vs Placebo (Scheinmedikament das nur Zucker enthält)
    Avatar
    Magnetfeldfredy
    schrieb am 23.04.09 18:10:45
    Beitrag Nr. 146 (37.028.684)
    Antwort auf Beitrag Nr.: 37.028.580 von VaJo am 23.04.09 18:02:29Und dann kannst Du auch einsteigen und auf so einen big move hoffen!:D
    Denkst Du wirklich den Prostatakrebskranken wird nach den ereichten primary endpoint:D, im overall survival:eek:, der Gold Standart war:eek:, Provenge vorenthalten!
    In was hast Du Dich hineingesteigert, freu Dich für die Kranken und vielleicht findest Du ein anderes Investment wo Du auch mal richtig durchstrarten kannst z.B.SPPI?, oder?
    Avatar
    Magnetfeldfredy
    schrieb am 23.04.09 18:27:07
    Beitrag Nr. 147 (37.028.850)
    Antwort auf Beitrag Nr.: 37.028.655 von VaJo am 23.04.09 18:08:49Wurde auch 2007 ein primary endpoint erreicht, nein, im Gegensatz zu jetzt und das ist die Voraussetzung für eine Zulassung!:D
    Avatar
    VaJo
    schrieb am 23.04.09 18:41:56
    Beitrag Nr. 148 (37.028.993)
    Antwort auf Beitrag Nr.: 37.028.850 von Magnetfeldfredy am 23.04.09 18:27:07Wurde auch 2007 ein primary endpoint erreicht, nein,

    Du weist aber schon was Du gekauft hast oder?
    Avatar
    Magnetfeldfredy
    schrieb am 23.04.09 19:17:09
    Beitrag Nr. 149 (37.029.326)
    Antwort auf Beitrag Nr.: 37.028.993 von VaJo am 23.04.09 18:41:56Es geht nicht um irgendeinen primary endpoint, der primary endpoint war diesmal das overall survival, der Gold standard und der wurde erreicht:D, ich weiß genau was ich gekauft habe!:cool:

    Ich weiß auch, daß ich sehr viel Glück gehabt habe, daß dieser primary endpoint erreicht wurde! Aber so ist es im Leben manchmal hast Du Glück und wie bei GPC hatte ich Pech!

    Glück bedeutet, daß die Kranken eine revolutinäre Immuntherapie erhalten werden die im Gegensatz zur Chemo viel verträglicher sein wird und vielleicht hat Dendreon mit Neuvenge den nächsten Immunaktivierer gegen Brustkrebs, ich hoffe es für alle Frauen die davon betroffen sind, Du nicht?
    Avatar
    _poseidon
    schrieb am 23.04.09 21:25:22
    Beitrag Nr. 150 (37.030.504)
    gibt es zum ende noch eine really?

    4/23/2009 3:24:33 PM Market Open
    NASDAQ Last Sale
    0.6338 0.03 5.00%

    GLTA
    Avatar
    _poseidon
    schrieb am 23.04.09 21:40:33
    Beitrag Nr. 151 (37.030.631)
    ups
    das e könnt ihr behalten :)
    Avatar
    VaJo
    schrieb am 24.04.09 12:59:24
    Beitrag Nr. 152 (37.034.485)
    CEGE Director L. Kopp hat gestern und vorgestern wieder jeweils 200.000 Stücke, einmal zu 0,589 und zu 0,609 gekauft.

    Warum macht er das?
    :D
    Avatar
    Magnetfeldfredy
    schrieb am 24.04.09 13:11:53
    Beitrag Nr. 153 (37.034.600)
    Antwort auf Beitrag Nr.: 37.034.485 von VaJo am 24.04.09 12:59:24Vielleicht wird Cell Genesys von Dendreon von 1 US Dollar übernommen?:laugh:
    Avatar
    VaJo
    schrieb am 24.04.09 13:43:32
    Beitrag Nr. 154 (37.034.837)
    Könnte sein, weil GVax besser als Provenge ist. ;)
    Avatar
    _poseidon
    schrieb am 24.04.09 15:35:02
    Beitrag Nr. 155 (37.035.738)
    4/24/2009 9:34:23 AM Market Open
    NASDAQ Last Sale
    0.6395 0.03 4.92%
    Avatar
    Magnetfeldfredy
    schrieb am 24.04.09 22:23:31
    Beitrag Nr. 156 (37.038.950)
    Antwort auf Beitrag Nr.: 37.034.837 von VaJo am 24.04.09 13:43:32Und Du bis Obama!:laugh:
    Avatar
    giesarazu
    schrieb am 26.04.09 12:20:29
    Beitrag Nr. 157 (37.042.086)
    Antwort auf Beitrag Nr.: 37.038.950 von Magnetfeldfredy am 24.04.09 22:23:31:rolleyes: watn spruch
    Avatar
    VaJo
    schrieb am 28.04.09 09:11:57
    Beitrag Nr. 158 (37.051.305)
    Director Kopp hat gestern wieder zugeschlagen 400.000 Stück. Mittlerweile schwimmt er in Cell Genesys Aktien.

    Die Frage ist, warum sammelt er seit Mitte April soviele Aktien ein?
    Avatar
    giesarazu
    schrieb am 28.04.09 14:16:10
    Beitrag Nr. 159 (37.053.562)
    Antwort auf Beitrag Nr.: 37.051.305 von VaJo am 28.04.09 09:11:57echt, schon wieder ??? is ja der hamma...
    Avatar
    VaJo
    schrieb am 28.04.09 19:17:47
    Beitrag Nr. 160 (37.056.338)
    Schaut euch mal nach Biotechs um die im Bereich Vaccine unterwegs sind. Und überlegt euch welche ihr Morgen kaufen wollt.

    Wenn Dendreon nachher Fakten präsentiert die überzeugen, beginnt spätestens morgen ein run auf alles wo Vaccine draufsteht.

    "Normale" Pharmas und Biotechs werden dann unter die Räder kommen.

    Sind die Zahlen so naja ganz gut. Passiert gar nix...
    Avatar
    giesarazu
    schrieb am 28.04.09 20:12:42
    Beitrag Nr. 161 (37.056.823)
    Antwort auf Beitrag Nr.: 37.056.338 von VaJo am 28.04.09 19:17:47sag mal, was ist denn gerade hier fuern kursrutsch passiert. komme vonna arbeit heim, da steht der kurs auf 0,50 und ploetzlich, 15 min. spaeter auf 0,77 ?????
    Avatar
    VaJo
    schrieb am 28.04.09 20:24:34
    Beitrag Nr. 162 (37.056.942)
    Antwort auf Beitrag Nr.: 37.056.823 von giesarazu am 28.04.09 20:12:42DNDN hat abgekotzt und die Anleger wurden wieder mal abgezockt... :look:

    Bei DNDN gibts ab heute wieder viele Tausend Neue Langfristanleger :D
    Avatar
    giesarazu
    schrieb am 28.04.09 20:44:01
    Beitrag Nr. 163 (37.057.102)
    Antwort auf Beitrag Nr.: 37.056.942 von VaJo am 28.04.09 20:24:34:laugh: jetzt schnall ichs auch endlich... sollte mal mehr querdenken
    Avatar
    VaJo
    schrieb am 28.04.09 20:44:31
    Beitrag Nr. 164 (37.057.108)
    Kopp wird Ende der Woche noch reicher sein!

    Auf CNN gabs eben ein Bericht in dem GVax erwähnt wurde!!
    Avatar
    VaJo
    schrieb am 28.04.09 20:45:09
    Beitrag Nr. 165 (37.057.114)
    Aktuell 0,72 Dollar PPS
    Avatar
    VaJo
    schrieb am 28.04.09 20:47:46
    Beitrag Nr. 166 (37.057.140)
    Wenn CEGE jetzt nach den DNDN Daten GVax neu auflegt wird richtig wild. Kopp wird sein Shares kaum anbieten weil er weiß das die GVax Daten besser waren als die von Provenge.
    Avatar
    Larry_1
    schrieb am 28.04.09 21:05:11
    Beitrag Nr. 167 (37.057.330)
    Mann oh Mann
    vor 2 Stunden habe ich die CEGE das letzte mal angeschaut und jetzt das :kiss:
    Interessant ist, das um 19.30 Uhr die CEGE durch DNDN auch kurzzeitig runtergebrochen ist....

    Egal, wie das mit DNDN weitergeht, nach 800% Anstieg muß die Aktie
    sich zwangsläufig entladen.

    Der Clevere hat die letzten Tage in CEGE umgeschichtet :D
    Avatar
    Larry_1
    schrieb am 28.04.09 21:08:06
    Beitrag Nr. 168 (37.057.361)
    Antwort auf Beitrag Nr.: 37.057.114 von VaJo am 28.04.09 20:45:09VaJo, Danke für Deine guten Beiträge :)
    Avatar
    VaJo
    schrieb am 28.04.09 21:09:52
    Beitrag Nr. 169 (37.057.383)
    Pass aber auf mit CEGE. Das ist übelste Spekulation. Keiner weis was. Nur das der Chef seit Tagen Aktienpakete in Hundertausender Stücken kauft.

    Das kann jetzt bedeuten:

    1. GVax wird wieder belebt
    2. Verkauf von GVax
    3. Verkauf on CEGE
    4. Riesen Beschiss!

    Alles ist möglich. Hier gehts doch im Moment nirgends mit rechten Dingen zu.

    ;)
    Avatar
    VaJo
    schrieb am 28.04.09 21:19:19
    Beitrag Nr. 170 (37.057.502)
    Hmm,... was jetzt los..
    Avatar
    Larry_1
    schrieb am 28.04.09 21:19:22
    Beitrag Nr. 171 (37.057.503)
    Antwort auf Beitrag Nr.: 37.057.383 von VaJo am 28.04.09 21:09:52Ich gehe mal von Punkt 1. - 3. aus

    Laß dich im DNDN Thread nicht fertig machen, dort liegen bei den meisten gerade die Nerven blank

    Ich geh wieder offline

    good trade :cool:
    Avatar
    VaJo
    schrieb am 28.04.09 21:22:05
    Beitrag Nr. 172 (37.057.540)
    Jo Dir auch

    Gute Nacht ;)
    Avatar
    Larry_1
    schrieb am 28.04.09 21:55:54
    Beitrag Nr. 173 (37.057.899)
    hmm, mußte dochmal reinschauen
    sieht gut aus und Volumen paßt auch :cool:
    Avatar
    VaJo
    schrieb am 28.04.09 22:03:19
    Beitrag Nr. 174 (37.057.992)
    Antwort auf Beitrag Nr.: 37.057.899 von Larry_1 am 28.04.09 21:55:54Ja ist wirklich spannend.
    Avatar
    VaJo
    schrieb am 28.04.09 22:05:02
    Beitrag Nr. 175 (37.058.002)
    Im Dendreon Bord auf Yahoo spielen sich Dramen ab. Manche haben da Anscheinend "ALL IN" gespielt. :(
    Avatar
    Larry_1
    schrieb am 29.04.09 08:39:04
    Beitrag Nr. 176 (37.059.187)
    Antwort auf Beitrag Nr.: 37.058.002 von VaJo am 28.04.09 22:05:02guten Morgen


    Ich sag nur eins
    wie so oft
    Gier frißt Hirn, dadurch geht die Realität verloren


    CEGE After Hours 0,87 :D
    Avatar
    VaJo
    schrieb am 29.04.09 09:10:53
    Beitrag Nr. 177 (37.059.433)
    Shorten gehört verboten! Was da abgezogen wurde war kriminell. Ich weis nicht wieviele Millionen in Panik verkauft wurden, nur um danach von anderen aufgesammelt zu werden. Sehr schlimm. Jetzt schauts wieder besser aus.

    Ich bin gespannt wie es mit CEGE weiter geht.
    Avatar
    Larry_1
    schrieb am 29.04.09 12:39:47
    Beitrag Nr. 178 (37.061.324)
    um 12.17 Uhr 3K Kauf -----> wäre Klasse wenn das über die Vorbörse USA kommt (quasi Kuranpassung :confused: )
    Avatar
    Larry_1
    schrieb am 30.04.09 14:58:48
    Beitrag Nr. 179 (37.073.167)
    die Vorbörse sieht ja heute total besch... aus
    was ist da los :confused:
    Avatar
    VaJo
    schrieb am 03.05.09 20:25:14
    Beitrag Nr. 180 (37.086.136)
    Unser guter LeRoy Kopp läßt sich nicht beirren und kauft auf fleißig weiter Aktien seiner Firma. Am Donnerstag 150.000 für $ 0.573.
    Damit besitzt er nun fast 1/10 von CEGE nämlich 7.410.494 Stücke.

    Manche spekulieren er wolle die Firma übernehmen :laugh: da kann er noch die nächsten 10 Jahre weiterkaufen.

    Ich denke mal nachdem GVax an die John Hopkins Universität übergegangen ist, aber die Rechte bei Cell Genesys verbleiben wird sich bald aufklären warum Kopp ununterbrochen eigene Aktien kauft.

    Lassen wir uns mal überraschen.
    Avatar
    broker_muc
    schrieb am 04.05.09 07:10:14
    Beitrag Nr. 181 (37.086.894)
    Antwort auf Beitrag Nr.: 37.086.136 von VaJo am 03.05.09 20:25:14@LeRoy Kopp wer ist das, und woher weißt du das er soviel shares kauft. was ist derzeit das fundamentale Geschäftfeld von CEGE, womit machen sie Gewinne. ich Welche Phase ist GVax.meiner meinung nach wurde die forschung letzte jahr ergebnislos bzw. ohne zulassung eingestellt?
    Avatar
    VaJo
    schrieb am 04.05.09 10:35:00
    Beitrag Nr. 182 (37.087.941)
    Antwort auf Beitrag Nr.: 37.086.894 von broker_muc am 04.05.09 07:10:14Du erwartest doch nicht etwa von mir, dass ich Dir auf Deinen fordernden Ton irgendeine für dich nutzbringende Antwort gebe?

    Leute gibts... :laugh:
    Avatar
    VaJo
    schrieb am 04.05.09 10:36:54
    Beitrag Nr. 183 (37.087.959)
    Antwort auf Beitrag Nr.: 37.086.894 von broker_muc am 04.05.09 07:10:14Cell Genesys ist wertlos, hat kein Geschäft mehr und LeRoy Kopp ist ein Verrückter Investor der einfach nur Aktien kauft weil er Geld hat.
    :p
    Avatar
    VaJo
    schrieb am 04.05.09 11:14:55
    Beitrag Nr. 184 (37.088.246)
    http://phx.corporate-ir.net/phoenix.zhtml?c=98399&p=irol-sec

    Hier einfach die Fillings anschauen..
    Avatar
    broker_muc
    schrieb am 04.05.09 12:18:23
    Beitrag Nr. 185 (37.088.771)
    Antwort auf Beitrag Nr.: 37.088.246 von VaJo am 04.05.09 11:14:55ok ts,

    wo geht die Reise hin mit Cege, was haben die in der pipline und warum ist dr kurs stark gestiegen um dann wieder 50 prozent abzugeben?
    Avatar
    VaJo
    schrieb am 04.05.09 12:28:24
    Beitrag Nr. 186 (37.088.840)
    Es gibt keine Reise. Nur reine Spekulation. GVax ist die erfolgreichste Vaccine Therapie. Diese wurde in den VITAL Studien abgebrochen nachdem es zu unerklärten Todesfällen gekommen war, die vermutl. auf Taxotere/Prednisone zurück zu führen war.
    GVAx wurde anders als Provenge nicht vs Placebo getestet.

    Darauf bauen nun die Hoffnungen auf, daß in einer neuen Studie GVax vs Placebo getestet wird.

    Cell Genesys selbst hat letztes Jahr begonnen Labors und Einrichtungen zu verkaufen. Aktuell besitzt CEGE ca. 75 Mio Dollar Cash, ca. 1 Dollar/Aktie.
    GVax selbst wurde an die John Hopkins Universität gegeben. Die Rechte an GVax sind bei Cell Genesys verblieben.

    LeRoy Kopp ist privat Investor dem sehr gute Kontakte zu CEGE nachgesagt werden. Warum er Aktien kauft weis niemand. Vielleicht kauft der diese auch gar nicht für sich selbst.

    Alles in allem gibt es ausser den Kopp Käufen überhaupt nichts greifbares. Nur das wissen das GVax in einer falsch angelegten Studie getestet wurde.
    Avatar
    Larry_1
    schrieb am 07.05.09 18:06:24
    Beitrag Nr. 187 (37.121.938)
    !
    Dieser Beitrag wurde moderiert. Grund: Spammposting
    Avatar
    VaJo
    schrieb am 07.05.09 19:25:39
    Beitrag Nr. 188 (37.122.774)
    Kopp kauft auch wieder.
    Avatar
    Larry_1
    schrieb am 08.05.09 08:53:51
    Beitrag Nr. 189 (37.126.188)
    !
    Dieser Beitrag wurde moderiert. Grund: Spammposting
    Avatar
    Larry_1
    schrieb am 08.05.09 13:43:35
    Beitrag Nr. 190 (37.129.076)
    !
    Dieser Beitrag wurde moderiert. Grund: Spammposting
    Avatar
    Larry_1
    schrieb am 11.05.09 09:38:23
    Beitrag Nr. 191 (37.141.746)
    Antwort auf Beitrag Nr.: 37.122.774 von VaJo am 07.05.09 19:25:39ich habe meine am Freitag wieder gegeben :cool:
    Viel Glück
    Avatar
    VaJo
    schrieb am 11.05.09 18:47:06
    Beitrag Nr. 192 (37.146.976)
    NEU!!!


    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 11, 2009-- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that the Company expects to commence an exchange offer to exchange all of the $68.3 million aggregate principal amount of its outstanding 3.125% Convertible Senior Notes due in 2011 (“Existing Notes”) at a purchase price for each $1,000 principal amount of (i) $500 in cash, plus accrued interest, (ii) $140 worth of common stock equal to approximately 206 shares of common stock, and (iii) $310 of new 3.125% convertible senior notes due in May 2013 (“New Notes”).

    On May 5, 2009, Tang Capital Partners, LP filed a creditor derivative lawsuit in The Court of Chancery of the State of Delaware against Cell Genesys and its directors and executive officers. The lawsuit seeks, among other things, a declaration that the Company is insolvent and an injunction prohibiting previously disclosed executive retention payments. On May 10, 2009, the Company and Tang Capital Partners, LP entered into a settlement and exchange offer agreement pursuant to which the Company agreed to commence and offer to exchange all of the $68.3 million aggregate principal amount of Existing Notes at a purchase price for each $1,000 principal amount of (i) $500 in cash, plus accrued interest, (ii) $140 worth of common stock equal to approximately 206 shares of common stock, and (iii) $310 of New Notes. The New Notes will have a conversion price of $0.68 per share. If all holders of the Existing Notes tender into the exchange offer, the exchange is estimated to result in a cash expenditure of approximately $34.2 million plus approximately $0.2 million in accrued interest, the issuance of approximately 14.1 million new shares of common stock and approximately $21.2 of New Notes. Tang Capital Partners, LP has agreed to tender into the exchange offer and withdraw the lawsuit if the exchange offer is consummated. The exchange offer has a minimum exchange requirement of 87.5% of the outstanding aggregate principal amount of the Existing Notes. The settlement and exchange offer agreement is subject to a number of terms and conditions.

    This release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any security. An exchange offer will only be made pursuant to exchange offer documents that are to be made available to the holders of the Existing Notes and filed with the Securities and Exchange Commission (“SEC”). Holders of Existing Notes are advised to read the exchange offer documents when they become available, as these documents will contain important information about the exchange offer. Copies of the exchange offer documents and other filed documents will be available for free at the SEC’s website.

    About Cell Genesys, Inc.

    Cell Genesys is headquartered in South San Francisco, California. For additional information, please visit the Company’s website at www.cellgenesys.com.

    Forward-Looking Statements made herein about the Company, other than statements of historical fact, including statements about settlement of litigation, commencing an exchange offer, the results of an exchange offer, and cash expenditures and other costs to repurchase additional amounts of convertible notes are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks and uncertainties associated with the ability to successfully complete the exchange offer, the ability to successfully complete a strategic transaction, the occurrence of additional costs, expenses or other liabilities if the Company enters into a strategic transaction or pursues other strategic alternatives, including without limitation as a result of any litigation or claim asserted in connection with a potential transaction, the possibility that in the event of liquidation the stockholders may receive little or no distribution from the Company, the ability to raise capital, operating expense levels, and other risks. For information about these and other risks which may affect Cell Genesys, please see the Company's reports on Form 10-K, 10-Q, and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The Company assumes no obligation to update the forward-looking information in this press release.


    Source: Cell Genesys, Inc.

    Cell Genesys, Inc.Victoria Soares, 650-266-3200Investor Relations
    Avatar
    broker_muc
    schrieb am 12.05.09 10:23:36
    Beitrag Nr. 193 (37.151.484)
    Antwort auf Beitrag Nr.: 37.146.976 von VaJo am 11.05.09 18:47:06ok verstehe nicht ganz was bedeutes das für mich?

    habe 15.000 zu 0,53 $ gekauft!

    ich bin echt ratlos, ich bitte um hilfe?
    Avatar
    VaJo
    schrieb am 12.05.09 10:54:08
    Beitrag Nr. 194 (37.151.822)
    Antwort auf Beitrag Nr.: 37.151.484 von broker_muc am 12.05.09 10:23:36Erstmal würde ich gar nichts machen.
    Ich weis selbst noch nicht was das bedeutet.

    Aber Wahnsinn was manchmal für Beträge in solche Spielcasinos investiert werden. Wenn man als Anhalt max 1% seines Depots in Hochsprekulative Werte investiert, wie groß muss dann Dein Depot sein :eek:

    Wenn dem nicht so ist, würde ich mir vielleicht überlegen etwas zu reduzieren und einen anderen Wert anzuschauen der weniger Risikoreich ist.
    Avatar
    broker_muc
    schrieb am 12.05.09 11:14:48
    Beitrag Nr. 195 (37.152.057)
    Antwort auf Beitrag Nr.: 37.151.822 von VaJo am 12.05.09 10:54:08ich investiere 10 % in solchen sachen, ich erinner mich dies emeldung kam letzte woche auch bei DELTA PETROLEUM CORP. und sie ist gestiegen auch über die marke die im portfolio stand,

    an wenn kann mich wenden, wie man so eine nachricht deutet?
    Avatar
    VaJo
    schrieb am 12.05.09 18:30:46
    Beitrag Nr. 196 (37.157.321)
    Am 05.Mai hat Tang Capital Partners, eine Klage eingereicht. In dieser Klage sollte geklärt werden das CEGE zahlungsunfähig ist. Man hat sich mit Tang CP auf einen Vergleich in Höhe von 68,3 Millionen in Aktien und 34,2 Millionen Cashkosten geeinigt. Dazu kommen noch 14,1 Millionen neue Aktien für Tang CP. Wenn das Umtauschangebot vollzogen ist zieht Tang seine Klage zurück. Im Klartext versteh ich das so das Tang 87,5 % des Gesamtbetrags in Aktien haben möchte, die aus s.g. Convertible Senior Notes (Vorstand Bonus Aktien) kommen sollen die in den Jahren 2011 - 13 fällig werden.

    Auf gut deutsch, wer auch immer der Kläger wirklich ist, er möchte soviel Aktien wie möglich einsammeln. Warum auch immer.

    Kein Mensch weiß was da passiert. Fakt ist nur das man sich um Aktien eines scheinbar "toten" Unternehmens balgt, das aktuell an keiner Pipeline mehr arbeitet.
    Avatar
    VaJo
    schrieb am 12.05.09 18:34:23
    Beitrag Nr. 197 (37.157.359)
    Antwort auf Beitrag Nr.: 37.152.057 von broker_muc am 12.05.09 11:14:48Du hast 2 Möglichkeiten entweder Du verkaufst oder Du wartest ab. Wenn alle wüßten was sie machen sollten würde CEGE jetzt entweder bei 1 Cent oder bei 10 Dollar stehen.

    Auf keinen Fall würde ich mich trauen hier einen größeren Betrag zu investieren.

    Was übrigens für alle Biotechs gilt, die Schulden haben, wenig Cash, kein Produkt am Markt und noch Jahre von einer Zulassung entfernt sind.
    Avatar
    Larry_1
    schrieb am 20.05.09 12:42:42
    Beitrag Nr. 198 (37.217.715)
    Bin seit gestern bei SQNM investiert, natürlich in der Hoffnung auf steigende Kurse :cool:
    Avatar
    [KERN]Codex
    schrieb am 27.05.09 16:19:40
    Beitrag Nr. 199 (37.263.629)
    !
    Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users
    Avatar
    VaJo
    schrieb am 27.05.09 18:33:50
    Beitrag Nr. 200 (37.265.245)
    Antwort auf Beitrag Nr.: 37.263.629 von [KERN]Codex am 27.05.09 16:19:40Weis jetzt nicht ganz was das mit Cell Genesis zu tun hat? Aber vielleicht kannst Du ja den Zusammenhang darstellen ;)

    :D
    Avatar
    [KERN]Codex
    schrieb am 27.05.09 18:44:13
    Beitrag Nr. 201 (37.265.356)
    !
    Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users
    Avatar
    [KERN]Codex
    schrieb am 27.05.09 18:48:43
    Beitrag Nr. 202 (37.265.395)
    aber einen ceregene thread gibts nicht, und ein wenig richtig ist die news hier doch, denn:

    About Ceregene

    Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE - News) as well as Hamilton BioVentures and California Technology Partners.

    also doch richtig :D
    Avatar
    Jano57
    schrieb am 04.06.09 09:39:39
    Beitrag Nr. 203 (37.316.697)
    Kopp stockt weiter auf!!

    Lt. Filing 06.2009 und Stand 21.05.2009 hielt er knapp 12 Millionen Shares oder 13%

    was geht hier ab??

    finde keine News
    Avatar
    Jano57
    schrieb am 04.06.09 13:31:55
    Beitrag Nr. 204 (37.318.695)
    Es gibt noch keine pre-market Kurse!!

    wenn schon in Deutschland kaufen, abwarten bis die Börse drüben aufmacht:rolleyes:

    ist schon eine Frechheit was die hier taxen:(
    Avatar
    Larry_1
    schrieb am 15.06.09 19:19:17
    Beitrag Nr. 205 (37.396.382)
    Kann jemand von den Bio Freaks etwas zu JAZZ PHARMACEUTICALS schreiben, habe dort gerade einen Thread eröffnet und weiß net so recht weiter :laugh:
    Avatar
    Larry_1
    schrieb am 23.06.09 18:31:30
    Beitrag Nr. 206 (37.451.641)
    oh, oh, jetzt gehts aber kräftig down :eek:
    Avatar
    Jano57
    schrieb am 26.06.09 23:24:35
    Beitrag Nr. 207 (37.478.331)
    Na was da in der letzten Handelsminute und in der After-Hour Phase abgelaufen ist, habe ich in dieser Form auch noch nicht gesehen :confused:

    Sachen gibts:eek:
    Avatar
    Larry_1
    schrieb am 30.06.09 15:09:28
    Beitrag Nr. 208 (37.493.424)
    heute weiter up :lick:
    Avatar
    VaJo
    schrieb am 30.06.09 15:15:47
    Beitrag Nr. 209 (37.493.486)
    Hallo Larry,

    ich hab auch noch ein paar CEGE. Aber ich glaube die wird bald abgewickelt. Was meinst Du?
    Avatar
    Larry_1
    schrieb am 30.06.09 15:20:28
    Beitrag Nr. 210 (37.493.532)
    Avatar
    Icanfly
    schrieb am 30.06.09 15:29:35
    Beitrag Nr. 211 (37.493.617)
    Antwort auf Beitrag Nr.: 37.493.532 von Larry_1 am 30.06.09 15:20:28Da ist aber nicht mehr viel zu holen:rolleyes:
    Avatar
    VaJo
    schrieb am 30.06.09 15:39:51
    Beitrag Nr. 212 (37.493.706)
    Antwort auf Beitrag Nr.: 37.493.532 von Larry_1 am 30.06.09 15:20:28LOL danke!!

    :cool: jetzt hab ich ne PornoAktie im Depot :laugh:

    Da bin mal auf die HV's gepannt, wahrscheinlich gibts bei Zulassung StimmulanzGel für jeden :laugh::laugh:
    Avatar
    Larry_1
    schrieb am 30.06.09 15:46:34
    Beitrag Nr. 213 (37.493.774)
    Antwort auf Beitrag Nr.: 37.493.617 von Icanfly am 30.06.09 15:29:35
    abwarten !!
    Avatar
    Larry_1
    schrieb am 30.06.09 15:47:09
    Beitrag Nr. 214 (37.493.784)
    Antwort auf Beitrag Nr.: 37.493.706 von VaJo am 30.06.09 15:39:51ich bin bereit :)
    Avatar
    tom148
    schrieb am 30.06.09 22:31:00
    Beitrag Nr. 215 (37.497.028)
    Auf der homepage von cege befinden sich zwei Nachrichten aus dem Juni.
    Einer war zu entnehmen, dass das Risiko bestehe, dass, wenn die Fa. transformiert werde, die cege Aktien wertlos werden, bzw. nur eine geringe Entschädigung gezahlt werden könne, da alle Mittel, Kapital zu generieren, ausgeschöpft seien. Darauf habe ich meinen Bestand verkauft. Eine Nachfrage per email an die Fa. cege blieb unbeantwortet. Umso erstaunter bin ich zu sehen, wie cege in den Staaten gestern einen überproportionalen Kursanstieg verzeichnete. Heute nun die von Larry verlinkte news, dass die transformation in eine neue Gesellschaft beschlossene Sache ist. Das in Aussicht gestellte Risiko ist also eingetreten. Warum dann die Aktie steigt, ist mir ein Rätsel.

    lg t.
    Avatar
    dottore
    schrieb am 11.08.09 18:28:54
    Beitrag Nr. 216 (37.756.627)
    Antwort auf Beitrag Nr.: 37.497.028 von tom148 am 30.06.09 22:31:00cell gegesyshat einen Deal mit Biosante abgeschlossen, der soll Kohle im Mio Dollar-Bereich bringen ....
    Avatar
    Larry_1
    schrieb am 18.08.09 15:57:45
    Beitrag Nr. 217 (37.802.681)
    bin vorsichtshalber auch mal wieder dabei, man kann ja nie wissen...
    Avatar
    Joe_Trader
    schrieb am 18.08.09 16:27:04
    Beitrag Nr. 218 (37.803.016)
    Antwort auf Beitrag Nr.: 37.802.681 von Larry_1 am 18.08.09 15:57:45genau :D
    Avatar
    Joe_Trader
    schrieb am 19.08.09 05:12:33
    Beitrag Nr. 219 (37.806.661)
    Antwort auf Beitrag Nr.: 37.497.028 von tom148 am 30.06.09 22:31:00hallo :confused:
    du schreibst kein cash mehr da und ein paar wochen vorher noch über 60 mio Dollar cash vorhanden !!!!

    merger mit Biosante.
    cash wird kommen, zwischen 20-40 mio Dollar.

    irgendwie gibt es hier unstimmigkeiten.:keks:
    Avatar
    Larry_1
    schrieb am 19.08.09 19:03:09
    Beitrag Nr. 220 (37.812.731)
    also wenn es morgen weiterhin down geht, bin ich ganz schnell wieder weg :rolleyes:
    Avatar
    Joe_Trader
    schrieb am 20.08.09 15:14:35
    Beitrag Nr. 221 (37.818.275)
    Antwort auf Beitrag Nr.: 37.812.731 von Larry_1 am 19.08.09 19:03:09tja ist schon merkwürdig.

    es sollte eigentlich mal wieder hoch gehen.:rolleyes:
    Avatar
    Joe_Trader
    schrieb am 20.08.09 16:10:36
    Beitrag Nr. 222 (37.818.850)
    da werfen einige aber gefrustet :laugh::laugh::laugh:
    Avatar
    Joe_Trader
    schrieb am 20.08.09 16:33:22
    Beitrag Nr. 223 (37.819.138)
    Antwort auf Beitrag Nr.: 37.818.850 von Joe_Trader am 20.08.09 16:10:36wenn das nicht mal voreilig ist/war
    Avatar
    Joe_Trader
    schrieb am 24.08.09 16:51:05
    Beitrag Nr. 224 (37.839.348)
    yippie es geht abwärts :rolleyes::laugh::laugh::laugh:
    Avatar
    Joe_Trader
    schrieb am 24.08.09 19:25:43
    Beitrag Nr. 225 (37.840.743)
    Avatar
    Larry_1
    schrieb am 23.09.09 09:19:29
    Beitrag Nr. 226 (38.036.481)
    es geht aufwärts :cool:
    Avatar
    Larry_1
    schrieb am 23.09.09 15:57:42
    Beitrag Nr. 227 (38.040.427)
    :p
    Avatar
    Larry_1
    schrieb am 23.09.09 15:59:25
    Beitrag Nr. 228 (38.040.464)
    Avatar
    Larry_1
    schrieb am 23.09.09 16:07:42
    Beitrag Nr. 229 (38.040.600)
    falls jemand im englischen fit ist, was bedeutet diese Meldung??
    Avatar
    tom148
    schrieb am 30.09.09 14:11:27
    Beitrag Nr. 230 (38.085.795)
    Übernahme durch Biosante. Cege Aktionäre werden durch Biosante Aktien entschädigt. Für ca. 6 cege Aktien gibt es eine Biosante-aktie (0,18%).

    lg t.
    Avatar
    Larry_1
    schrieb am 02.10.09 11:08:24
    Beitrag Nr. 231 (38.101.865)
    Antwort auf Beitrag Nr.: 38.085.795 von tom148 am 30.09.09 14:11:27
    Danke :)




    Beitrag zu dieser Diskussion schreiben


    Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.

    Meistdiskutierte Aktien (24h)

    WertpapierBeiträge
    134
    44
    33
    30
    29
    26
    22
    21
    21
    18